Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
24,000 | 2021-07-25 00:00:00 UTC | 3 Dividend Stocks to Buy Hand Over Fist If the Market Crashes | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-hand-over-fist-if-the-market-crashes-2021-07-25 | null | null | I am absolutely convinced that the stock market is going to crash. However, I don't have the remotest idea when it will happen. It could be in 2021 or it could be several years from now.
There's also something else that I'm convinced about: Buying certain dividend stocks when the market crashes is a smart idea. You can... | AbbVie AbbVie (NYSE: ABBV) already offers a juicy dividend yield of more than 4.5%. AbbVie is only one dividend hike away from joining the group of stocks known as Dividend Kings -- S&P 500 members with at least 50 consecutive years of dividend increases. What would happen with AbbVie during a stock market crash? | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, and Pfizer. AbbVie AbbVie (NYSE: ABBV) already offers a juicy dividend yield of more than 4.5%. AbbVie is only one dividend hike away from joining the group of stocks known as Dividend Kings -... | AbbVie is only one dividend hike away from joining the group of stocks known as Dividend Kings -- S&P 500 members with at least 50 consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, and Pfizer. AbbVie A... | AbbVie AbbVie (NYSE: ABBV) already offers a juicy dividend yield of more than 4.5%. AbbVie is only one dividend hike away from joining the group of stocks known as Dividend Kings -- S&P 500 members with at least 50 consecutive years of dividend increases. What would happen with AbbVie during a stock market crash? |
24,001 | 2021-07-24 00:00:00 UTC | 3 Value Stocks to Buy for the Second Half of 2021 | ABBV | https://www.nasdaq.com/articles/3-value-stocks-to-buy-for-the-second-half-of-2021-2021-07-24 | null | null | Bargains are hard to find these days. That's true whether you're looking for a house, searching for a used car, or investing in stocks.
Most stocks are priced at hefty premiums right now. However, there are still some bargains to be found. Here are three value stocks to buy for the second half of 2021.
Image source: Ge... | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 9.4 times expected earnings. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. Granted, most of that was the result of AbbVie's acquisition of Allergan. | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 9.4 times expected earnings. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. Granted, most of that was the result of AbbVie's acquisition of Allergan. | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie and Pfizer. AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 9.4 times expected earnings. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. | AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at only 9.4 times expected earnings. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. Granted, most of that was the result of AbbVie's acquisition of Allergan. |
24,002 | 2021-07-23 00:00:00 UTC | Notable ETF Inflow Detected - XLV, JNJ, UNH, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-jnj-unh-abbv-2021-07-23 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $720.6 million dollar inflow -- that's a 2.4% increase week over week in outstanding units (from ... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is up about 0.6%, UnitedHealth Group Inc (Symbol: UNH) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is up about 0.6%, UnitedHealth Group Inc (Symbol: UNH) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year p... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is up about 0.6%, UnitedHealth Group Inc (Symbol: UNH) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is up about 0.6%, UnitedHealth Group Inc (Symbol: UNH) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... |
24,003 | 2021-07-22 00:00:00 UTC | 3 Biotechs That Could Make Big Acquisitions This Year | ABBV | https://www.nasdaq.com/articles/3-biotechs-that-could-make-big-acquisitions-this-year-2021-07-22 | null | null | Who wants to make a deal? That's the question in the biotech world right now with valuations down from earlier this year. Several big drugmakers have both a reason to make an acquisition as well as the financial strength to do so. In this Motley Fool Live video recorded on July 14, Motley Fool contributors Keith Speigh... | With that context, I'll give you three companies, AbbVie (NYSE: ABBV), which is facing coming biosimilar competition for its mega-blockbuster, Humira. I'd say those three are most likely to be making deals in the not-too-distant future, so AbbVie, Gilead, and Vertex. AbbVie had the big acquisition of Allergan, I guess ... | Keith Speights owns shares of AbbVie, SPDR S&P Biotech, and Vertex Pharmaceuticals. With that context, I'll give you three companies, AbbVie (NYSE: ABBV), which is facing coming biosimilar competition for its mega-blockbuster, Humira. I'd say those three are most likely to be making deals in the not-too-distant future,... | With that context, I'll give you three companies, AbbVie (NYSE: ABBV), which is facing coming biosimilar competition for its mega-blockbuster, Humira. I'd say those three are most likely to be making deals in the not-too-distant future, so AbbVie, Gilead, and Vertex. AbbVie had the big acquisition of Allergan, I guess ... | With that context, I'll give you three companies, AbbVie (NYSE: ABBV), which is facing coming biosimilar competition for its mega-blockbuster, Humira. I'd say those three are most likely to be making deals in the not-too-distant future, so AbbVie, Gilead, and Vertex. AbbVie had the big acquisition of Allergan, I guess ... |
24,004 | 2021-07-21 00:00:00 UTC | Drugmakers, pharmacies next targets for U.S. opioid settlements | ABBV | https://www.nasdaq.com/articles/drugmakers-pharmacies-next-targets-for-u.s.-opioid-settlements-2021-07-21 | null | null | By Brendan Pierson
NEW YORK, July 21 (Reuters) - With a $26 billion nationwide settlement in sight over claims that the three largest U.S. drug distributors and Johnson & Johnson JNJ.N helped fuel a nationwide opioid epidemic, state and local governments will soon turn their attention to pharmacies and a handful of dru... | The deal also would not include drugmakers AbbVie Inc ABBV.N, Teva Pharmaceutical Industries Ltd TEVA.TA or Endo International Plc ENDP.O, which have been accused of misleadingly marketing their pain medicines as safe. AbbVie and Endo did not immediately respond to requests for comment on settlement negotiations. More ... | AbbVie and Endo did not immediately respond to requests for comment on settlement negotiations. The deal also would not include drugmakers AbbVie Inc ABBV.N, Teva Pharmaceutical Industries Ltd TEVA.TA or Endo International Plc ENDP.O, which have been accused of misleadingly marketing their pain medicines as safe. By Br... | The deal also would not include drugmakers AbbVie Inc ABBV.N, Teva Pharmaceutical Industries Ltd TEVA.TA or Endo International Plc ENDP.O, which have been accused of misleadingly marketing their pain medicines as safe. AbbVie and Endo did not immediately respond to requests for comment on settlement negotiations. By Br... | AbbVie and Endo did not immediately respond to requests for comment on settlement negotiations. The deal also would not include drugmakers AbbVie Inc ABBV.N, Teva Pharmaceutical Industries Ltd TEVA.TA or Endo International Plc ENDP.O, which have been accused of misleadingly marketing their pain medicines as safe. News ... |
24,005 | 2021-07-20 00:00:00 UTC | Drug distributors to pay up to $1.1 bln to settle New York opioid case | ABBV | https://www.nasdaq.com/articles/drug-distributors-to-pay-up-to-%241.1-bln-to-settle-new-york-opioid-case-2021-07-20-0 | null | null | By Brendan Pierson and Nate Raymond
NEW YORK, July 20 (Reuters) - The three largest U.S. drug distributors agreed mid-trial to pay up to $1.1 billion to settle claims by New York state and two of its biggest counties over their role in the nationwide opioid epidemic, the state's attorney general said on Tuesday.
McKess... | The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers - Endo International Plc ENDP.O, Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit. The deal with New York Attorney General Letitia James and the populous Long Island counties of N... | The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers - Endo International Plc ENDP.O, Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit. By Brendan Pierson and Nate Raymond NEW YORK, July 20 (Reuters) - The three largest U.S. drug di... | The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers - Endo International Plc ENDP.O, Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit. By Brendan Pierson and Nate Raymond NEW YORK, July 20 (Reuters) - The three largest U.S. drug di... | The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers - Endo International Plc ENDP.O, Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit. By Brendan Pierson and Nate Raymond NEW YORK, July 20 (Reuters) - The three largest U.S. drug di... |
24,006 | 2021-07-20 00:00:00 UTC | Have $2,000? 2 All-Weather Stocks to Buy This Month | ABBV | https://www.nasdaq.com/articles/have-%242000-2-all-weather-stocks-to-buy-this-month-2021-07-20 | null | null | Finding stocks that can guide your portfolio to safe harbor when the next market storm strikes doesn't have to be complicated. It's true that stocks are incredibly expensive right now and some just can't justify their nosebleed valuations. Even so, you can find compelling buying opportunities if you know where to look.... | AbbVie is another well-known pharmaceutical company working on several different CFTR modulators, but its candidates are still in either phase 1 or 2 clinical trials. Two top-notch stocks from very different sectors -- healthcare and e-commerce -- have continued to generate high levels of balance sheet and business gro... | AbbVie is another well-known pharmaceutical company working on several different CFTR modulators, but its candidates are still in either phase 1 or 2 clinical trials. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) is by far one of the most important players in the global multi-billion-dollar cystic fibros... | AbbVie is another well-known pharmaceutical company working on several different CFTR modulators, but its candidates are still in either phase 1 or 2 clinical trials. Even if these drugs do eventually gain approval down the line, the opportunity within the CF drug market and even more specifically within the CFTR modul... | AbbVie is another well-known pharmaceutical company working on several different CFTR modulators, but its candidates are still in either phase 1 or 2 clinical trials. The global CF drug market is on track to hit a global valuation of about $14 billion by the year 2025, according to Grand View Research. Meanwhile, an Ap... |
24,007 | 2021-07-19 00:00:00 UTC | 3 High-Yield Dividend Aristocrats To Buy Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-aristocrats-to-buy-now-2021-07-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Income investors are always searching for high yields, which are hard to find with today’s historically low interest rates and record-high stock prices. But investors should not sacrifice dividend safety in favor of higher yields. This is why high-quality d... | 7 A-Rated Retirement Stocks to Buy to for Your Golden Years These three dividend stocks from the list have yields above 4% and can raise their dividends each year due to their strong business models: Chevron Corporation (NYSE:CVX) AbbVie Inc. (NYSE:ABBV) Realty Income (NYSE:O) Dividend Stocks: Chevron Corporation (CVX)... | 7 A-Rated Retirement Stocks to Buy to for Your Golden Years These three dividend stocks from the list have yields above 4% and can raise their dividends each year due to their strong business models: Chevron Corporation (NYSE:CVX) AbbVie Inc. (NYSE:ABBV) Realty Income (NYSE:O) Dividend Stocks: Chevron Corporation (CVX)... | 7 A-Rated Retirement Stocks to Buy to for Your Golden Years These three dividend stocks from the list have yields above 4% and can raise their dividends each year due to their strong business models: Chevron Corporation (NYSE:CVX) AbbVie Inc. (NYSE:ABBV) Realty Income (NYSE:O) Dividend Stocks: Chevron Corporation (CVX)... | 7 A-Rated Retirement Stocks to Buy to for Your Golden Years These three dividend stocks from the list have yields above 4% and can raise their dividends each year due to their strong business models: Chevron Corporation (NYSE:CVX) AbbVie Inc. (NYSE:ABBV) Realty Income (NYSE:O) Dividend Stocks: Chevron Corporation (CVX)... |
24,008 | 2021-07-18 00:00:00 UTC | 4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021 | ABBV | https://www.nasdaq.com/articles/4-large-cap-healthcare-stocks-youll-want-on-your-radar-for-the-second-half-of-2021-2021-07 | null | null | The first half of 2021 brought plenty of big stories that impacted healthcare stocks -- from COVID-19 vaccines' success to pivotal decisions from the U.S. Food and Drug Administration (FDA). In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli talk about four large... | Then maybe a twofer -- AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) for the outcome of the JAK inhibitor saga. AbbVie's trying to get expanded use over Rinvoq, and then Pfizer has Xeljanz, which caused the controversy, and also abrocitinib. Then that would cause problems for AbbVie, as well as Pfizer's other JAK inhibito... | Then maybe a twofer -- AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) for the outcome of the JAK inhibitor saga. Brian, so you mentioned Biogen, Moderna, AbbVie, and Pfizer. AbbVie's trying to get expanded use over Rinvoq, and then Pfizer has Xeljanz, which caused the controversy, and also abrocitinib. | Then maybe a twofer -- AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) for the outcome of the JAK inhibitor saga. AbbVie's trying to get expanded use over Rinvoq, and then Pfizer has Xeljanz, which caused the controversy, and also abrocitinib. Then that would cause problems for AbbVie, as well as Pfizer's other JAK inhibito... | Brian, so you mentioned Biogen, Moderna, AbbVie, and Pfizer. Then maybe a twofer -- AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) for the outcome of the JAK inhibitor saga. AbbVie's trying to get expanded use over Rinvoq, and then Pfizer has Xeljanz, which caused the controversy, and also abrocitinib. |
24,009 | 2021-07-17 00:00:00 UTC | Will This Biopharma Company Continue to Crush It? | ABBV | https://www.nasdaq.com/articles/will-this-biopharma-company-continue-to-crush-it-2021-07-17 | null | null | If you've ever had a migraine or know someone who has, you know it's something you would pretty much do anything to get rid of. Biohaven Pharmaceutical Holding (NYSE: BHVN), a commercial-stage pharma company focused on drugs that target the nervous system, is keenly aware of the relief that migraine treatment can bring... | A primary competitor to Nurtec is Ubrelvy, from Abbvie (NYSE: ABBV). Biohaven Pharmaceutical Holding (NYSE: BHVN), a commercial-stage pharma company focused on drugs that target the nervous system, is keenly aware of the relief that migraine treatment can bring to these sufferers. Of the 1,000 survey respondents, only ... | A primary competitor to Nurtec is Ubrelvy, from Abbvie (NYSE: ABBV). Open doors to revenue Since the launch of Nurtec in February 2020, the company has pulled in $200 million in revenue due to the migraine drug. On July 7 of this year, the company announced that preliminary product revenue total was $93 million for the... | A primary competitor to Nurtec is Ubrelvy, from Abbvie (NYSE: ABBV). Biohaven Pharmaceutical Holding (NYSE: BHVN), a commercial-stage pharma company focused on drugs that target the nervous system, is keenly aware of the relief that migraine treatment can bring to these sufferers. Open doors to revenue Since the launch... | A primary competitor to Nurtec is Ubrelvy, from Abbvie (NYSE: ABBV). In May of this year, Nurtec received a new FDA approval, this time for use in preventing migraines. COVID-19 impact A preventative treatment would be welcome relief to the over 40 million people in the U.S. who suffer from migraines. |
24,010 | 2021-07-16 00:00:00 UTC | AbbVie, Lilly face fresh delays in FDA approval for expanded use of arthritis drugs | ABBV | https://www.nasdaq.com/articles/abbvie-lilly-face-fresh-delays-in-fda-approval-for-expanded-use-of-arthritis-drugs-2021-07 | null | null | AbbVie Inc ABBV.N and ELi Lilly & Co LLY.N are facing fresh delays in the approval of their respective rheumatoid arthritis drugs for treating chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns.
The treatment, called JAK inhibitors, blocks inflammation-caus... | AbbVie Inc ABBV.N and ELi Lilly & Co LLY.N are facing fresh delays in the approval of their respective rheumatoid arthritis drugs for treating chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The decision on Abbvie's Rinvoq and Lilly's Baricitinib for tr... | AbbVie Inc ABBV.N and ELi Lilly & Co LLY.N are facing fresh delays in the approval of their respective rheumatoid arthritis drugs for treating chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The decision on Abbvie's Rinvoq and Lilly's Baricitinib for tr... | AbbVie Inc ABBV.N and ELi Lilly & Co LLY.N are facing fresh delays in the approval of their respective rheumatoid arthritis drugs for treating chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The decision on Abbvie's Rinvoq and Lilly's Baricitinib for tr... | AbbVie Inc ABBV.N and ELi Lilly & Co LLY.N are facing fresh delays in the approval of their respective rheumatoid arthritis drugs for treating chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The decision on Abbvie's Rinvoq and Lilly's Baricitinib for tr... |
24,011 | 2021-07-15 00:00:00 UTC | Here's Why Galapagos Stock Is Falling Today | ABBV | https://www.nasdaq.com/articles/heres-why-galapagos-stock-is-falling-today-2021-07-15 | null | null | What happened
Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday.
So what
Follow... | Skyrizi, a successful psoriasis treatment AbbVie launched in 2019 led to 90% improvements for 75% of patients treated in clinical trials leading to its approval. What happened Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug c... | Skyrizi, a successful psoriasis treatment AbbVie launched in 2019 led to 90% improvements for 75% of patients treated in clinical trials leading to its approval. Galapagos stock is sliding today because the company reported disappointing data for the first clinical-stage candidate to emerge from the Toledo program. Unf... | Skyrizi, a successful psoriasis treatment AbbVie launched in 2019 led to 90% improvements for 75% of patients treated in clinical trials leading to its approval. Galapagos stock is sliding today because the company reported disappointing data for the first clinical-stage candidate to emerge from the Toledo program. Fou... | Skyrizi, a successful psoriasis treatment AbbVie launched in 2019 led to 90% improvements for 75% of patients treated in clinical trials leading to its approval. Galapagos stock is sliding today because the company reported disappointing data for the first clinical-stage candidate to emerge from the Toledo program. Fou... |
24,012 | 2021-07-15 00:00:00 UTC | Britain fines drugmakers $360 million for overcharging NHS | ABBV | https://www.nasdaq.com/articles/britain-fines-drugmakers-%24360-million-for-overcharging-nhs-2021-07-15-0 | null | null | Adds details from CMA statement
July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network in relation to supply of hydrocortisone tablets.
The companies engaged in p... | Adds details from CMA statement July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network in relation to supply of hydrocortisone tablets. The watchdog said the firm... | The companies engaged in practices including buying potential rivals to keep them off the market, increase prices of the drugs as the sole provider and paying off competition, the Competition and Markets Authority said. The regulator fined Actavis UK, Auden Mckenzie, Allergan Plc, Accord Healthcare, Intas Pharmaceutica... | Adds details from CMA statement July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network in relation to supply of hydrocortisone tablets. The companies engaged in p... | The companies engaged in practices including buying potential rivals to keep them off the market, increase prices of the drugs as the sole provider and paying off competition, the Competition and Markets Authority said. Auden Mckenzie and Actavis UK together will pay 221.1 million pounds. The watchdog said the firms ch... |
24,013 | 2021-07-15 00:00:00 UTC | Britain fines drugmakers $360 million for overcharging NHS | ABBV | https://www.nasdaq.com/articles/britain-fines-drugmakers-%24360-million-for-overcharging-nhs-2021-07-15 | null | null | July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network for hydrocortisone tablets for almost a decade.
The Competition and Markets Authority said it has fined Acc... | July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network for hydrocortisone tablets for almost a decade. The Competition and Markets Authority said it has fined Acc... | July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network for hydrocortisone tablets for almost a decade. The Competition and Markets Authority said it has fined Acc... | July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network for hydrocortisone tablets for almost a decade. The Competition and Markets Authority said it has fined Acc... | July 15 (Reuters) - Britain's competition regulator said on Thursday it has fined several drugmakers a total of more than 260 million pounds ($360 million) for overcharging the state-backed NHS healthcare network for hydrocortisone tablets for almost a decade. The Competition and Markets Authority said it has fined Acc... |
24,014 | 2021-07-14 00:00:00 UTC | Best Health Care Stocks To Buy Now? 3 To Know | ABBV | https://www.nasdaq.com/articles/best-health-care-stocks-to-buy-now-3-to-know-2021-07-14 | null | null | 3 Hot Health Care Stocks To Add To Your July Watchlist
You can’t deny that health care has been and continues to be a top priority in the world today. By extension, this would see health care stocks continue to gain traction in the stock market today. Indeed, as the world deals with the coronavirus pandemic and its var... | Last week, the company announced a new collaboration with Biogen (NASDAQ: BIIB) and AbbVie to create the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease. Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) UnitedH... | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) UnitedHealth Group Inc. (NYSE: UNH) Pfizer Inc. Pfizer is a multinational health care company that is headquartered in New York City. Based on its latest quarter financials in April, AbbVie posted net revenue of $13.01 bi... | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) UnitedHealth Group Inc. (NYSE: UNH) Pfizer Inc. Pfizer is a multinational health care company that is headquartered in New York City. Last week, the company announced a new collaboration with Biogen (NASDAQ: BIIB) and Abb... | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) UnitedHealth Group Inc. (NYSE: UNH) Pfizer Inc. Pfizer is a multinational health care company that is headquartered in New York City. Last week, the company announced a new collaboration with Biogen (NASDAQ: BIIB) and Abb... |
24,015 | 2021-07-13 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 14, 2021 | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-ex-dividend-date-scheduled-for-july-14-2021-2021-07-13 | null | null | AbbVie Inc. (ABBV) will begin trading ex-dividend on July 14, 2021. A cash dividend payment of $1.3 per share is scheduled to be paid on August 16, 2021. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that ABBV has paid the same divid... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2021 as 19.51%, compared to an industry average of 7%. For more information on the declaration, record and payment dates, visit the ABBV Divide... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. ABBV's current earnings per share, an indicator of a company's profitability, is $2.83. The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF (ABBV) First Trust Morningstar ETF ... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF (ABBV) First Trust... | The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF (ABBV) First Trust Morningstar ETF (ABBV) WBI Bull-Bear Rising Income 1000 ETF (ABBV) WBI BullBear Value 3000 ETF (ABBV) WBI BullBear Yield 3000 ETF (ABBV). AbbVie Inc. (ABBV) will begin trading ex-dividend on July 14, 2021. Shar... |
24,016 | 2021-07-12 00:00:00 UTC | Ex-Dividend Reminder: Abbott Laboratories, AbbVie and BankUnited | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbott-laboratories-abbvie-and-bankunited-2021-07-12 | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/21, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and BankUnited Inc. (Symbol: BKU) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories will pay its quarterly dividend of $0.45 on 8/16/21, AbbVie ... | If they do continue, the current estimated yields on annualized basis would be 1.51% for Abbott Laboratories, 4.43% for AbbVie Inc, and 2.20% for BankUnited Inc.. Looking at the universe of stocks we cover at Dividend Channel, on 7/14/21, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and BankUnited Inc.... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/21, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and BankUnited Inc. (Symbol: BKU) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories will pay its quarterly dividend of $0.45 on 8/16/21, AbbVie ... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/21, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and BankUnited Inc. (Symbol: BKU) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories will pay its quarterly dividend of $0.45 on 8/16/21, AbbVie ... | If they do continue, the current estimated yields on annualized basis would be 1.51% for Abbott Laboratories, 4.43% for AbbVie Inc, and 2.20% for BankUnited Inc.. Looking at the universe of stocks we cover at Dividend Channel, on 7/14/21, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and BankUnited Inc.... |
24,017 | 2021-07-07 00:00:00 UTC | Got $5,000? Buy and Hold These 3 Value Stocks for Years | ABBV | https://www.nasdaq.com/articles/got-%245000-buy-and-hold-these-3-value-stocks-for-years-2021-07-07 | null | null | Whether you are worried about a recession or just want investments you can safely hang on to for years, value stocks are great options to consider putting your money into. With modest valuations and strong fundamentals, these are the types of stocks that can lead to long-term wealth. Some of them pay recurring dividend... | If you've got $5,000 that you can afford to invest, then three stocks that should rank high on your list of possible investments are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and Dell (NYSE: DELL). AbbVie AbbVie may look like an expensive buy when you look at its price-to-earnings (P/E) ratio, which today is mo... | If you've got $5,000 that you can afford to invest, then three stocks that should rank high on your list of possible investments are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and Dell (NYSE: DELL). When AbbVie reported its first-quarter results for the period ending March 31, its sales looked incredible at $13 ... | If you've got $5,000 that you can afford to invest, then three stocks that should rank high on your list of possible investments are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and Dell (NYSE: DELL). AbbVie AbbVie may look like an expensive buy when you look at its price-to-earnings (P/E) ratio, which today is mo... | If you've got $5,000 that you can afford to invest, then three stocks that should rank high on your list of possible investments are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and Dell (NYSE: DELL). AbbVie AbbVie may look like an expensive buy when you look at its price-to-earnings (P/E) ratio, which today is mo... |
24,018 | 2021-07-07 00:00:00 UTC | iShares Russell Top 200 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-top-200-growth-etf-experiences-big-outflow-2021-07-07 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Growth ETF (Symbol: IWY) where we have detected an approximate $254.1 million dollar outflow -- that's a 5.9% decrease week over week (from 27,850,000 to 26,200,000).... | Among the largest underlying components of IWY, in trading today Mastercard Inc (Symbol: MA) is down about 0.6%, Netflix Inc (Symbol: NFLX) is down about 0.9%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price p... | Among the largest underlying components of IWY, in trading today Mastercard Inc (Symbol: MA) is down about 0.6%, Netflix Inc (Symbol: NFLX) is down about 0.9%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price p... | Among the largest underlying components of IWY, in trading today Mastercard Inc (Symbol: MA) is down about 0.6%, Netflix Inc (Symbol: NFLX) is down about 0.9%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of IWY, in trading today Mastercard Inc (Symbol: MA) is down about 0.6%, Netflix Inc (Symbol: NFLX) is down about 0.9%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IWY Holdings page » The chart below shows the one year price p... |
24,019 | 2021-07-07 00:00:00 UTC | What Stocks To Buy Today? 4 Dividend Stocks To Watch In July 2021 | ABBV | https://www.nasdaq.com/articles/what-stocks-to-buy-today-4-dividend-stocks-to-watch-in-july-2021-2021-07-07 | null | null | Check Out These Top Dividend Stocks In The Stock Market Today
Amidst the volatility seen in the stock market recently, more investors could be turning towards dividend stocks. You see, it’s easy to forget about dividend stocks in a bullish market. After all, what’s the deal with a 10% annual dividend yield when some of... | For the uninitiated, AbbVie recently revealed that its treatment for ulcerative colitis, upadacitinib, met all of its primary and secondary endpoints set in a one-year-long Phase 3 study. According to AbbVie vice-chairman Michael Severino, the results demonstrate the drug’s potential as a treatment option for patients ... | Top Dividend Stocks To Buy [Or Avoid] Right Now Annaly Capital Management Inc. (NYSE: NLY) Clorox Co. (NYSE: CLX) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Annaly Capital Management First up the list is mortgage real estate investment trust (mREIT) Annaly Capital Management. 4 Tech Stocks To Consider AbbVie Ab... | Top Dividend Stocks To Buy [Or Avoid] Right Now Annaly Capital Management Inc. (NYSE: NLY) Clorox Co. (NYSE: CLX) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Annaly Capital Management First up the list is mortgage real estate investment trust (mREIT) Annaly Capital Management. 4 Tech Stocks To Consider AbbVie Ab... | AbbVie currently has a dividend yield of 4.5%. Top Dividend Stocks To Buy [Or Avoid] Right Now Annaly Capital Management Inc. (NYSE: NLY) Clorox Co. (NYSE: CLX) AbbVie Inc. (NYSE: ABBV) Chevron Corp. (NYSE: CVX) Annaly Capital Management First up the list is mortgage real estate investment trust (mREIT) Annaly Capital ... |
24,020 | 2021-07-06 00:00:00 UTC | Notable Tuesday Option Activity: ABBV, F, RBBN | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-abbv-f-rbbn-2021-07-06 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 23,592 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 42.6% of ABBV's average daily trading volume over ... | Especially high volume was seen for the $125 strike call option expiring September 17, 2021, with 3,039 contracts trading so far today, representing approximately 303,900 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (S... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 23,592 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 42.6% of ABBV's average daily trading volume over ... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 23,592 contracts have traded so far, representing approximately 2.4 million underlying shares. Especially high volume was seen for the $125 strike call option expiring... | Below is a chart showing RBBN's trailing twelve month trading history, with the $7.50 strike highlighted in orange: For the various different available expirations for ABBV options, F options, or RBBN options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy op... |
24,021 | 2021-07-06 00:00:00 UTC | 3 Dividend Stocks That Are Dirt Cheap Right Now | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-are-dirt-cheap-right-now-2021-07-06 | null | null | Descriptions like "income investor" and "value investor" are thrown around as if they're mutually exclusive. But they're not. There are many investors who equally belong to both groups.
However, it's challenging to be both an income investor and a value investor. There aren't very many stocks that provide solid dividen... | And while BMS can't claim the impressive track record that equals AbbVie, it has increased its dividend payout each year over the last decade. AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at just over nine times expected earnings. You don't just get a low valuation with AbbVie; you also get one of the best divi... | Bristol Myers Squibb Another big drugmaker, Bristol Myers Squibb (NYSE: BMY), sports an even more appealing valuation than AbbVie does. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie Shares of AbbVie (NYSE: ABBV) cu... | Viatris initiated its dividend program in May, so it doesn't have the history of dividends that AbbVie or Bristol Myers do. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie Shares of AbbVie (NYSE: ABBV) currently trad... | Viatris initiated its dividend program in May, so it doesn't have the history of dividends that AbbVie or Bristol Myers do. AbbVie Shares of AbbVie (NYSE: ABBV) currently trade at just over nine times expected earnings. You don't just get a low valuation with AbbVie; you also get one of the best dividends around. |
24,022 | 2021-07-05 00:00:00 UTC | Best Biotech Stocks To Buy In July 2021? 3 To Watch This Week | ABBV | https://www.nasdaq.com/articles/best-biotech-stocks-to-buy-in-july-2021-3-to-watch-this-week-2021-07-05 | null | null | 3 Top Biotech Stocks To Watch This Week
When looking for what stocks to buy in the stock market, investors could be turning towards biotech stocks once again. For one thing, the biotech industry is home to countless companies hard at work on the healthcare industry’s greatest problems. These range from the coronavirus ... | Last week, AbbVie revealed that its treatment for Ulcerative Colitis (UC), upadacitinib, met all of its primary and secondary endpoints set in a one-year-long Phase 3 study. According to AbbVie vice-chairman Michael Severino, the results demonstrate the drug’s potential as a treatment option for patients with moderate ... | Best Biotech Stocks To Buy [Or Sell] Now Moderna Inc. (NASDAQ: MRNA) Intellia Therapeutics Inc. (NASDAQ: NTLA) AbbVie Inc. (NYSE: ABBV) Moderna Inc. To begin with, we have one of the leading coronavirus vaccine companies now, Moderna. Source: TD Ameritrade TOS [Read More] 4 Artificial Intelligence Stocks To Watch Right... | Best Biotech Stocks To Buy [Or Sell] Now Moderna Inc. (NASDAQ: MRNA) Intellia Therapeutics Inc. (NASDAQ: NTLA) AbbVie Inc. (NYSE: ABBV) Moderna Inc. To begin with, we have one of the leading coronavirus vaccine companies now, Moderna. Source: TD Ameritrade TOS [Read More] 4 Artificial Intelligence Stocks To Watch Right... | Best Biotech Stocks To Buy [Or Sell] Now Moderna Inc. (NASDAQ: MRNA) Intellia Therapeutics Inc. (NASDAQ: NTLA) AbbVie Inc. (NYSE: ABBV) Moderna Inc. To begin with, we have one of the leading coronavirus vaccine companies now, Moderna. Source: TD Ameritrade TOS [Read More] 4 Artificial Intelligence Stocks To Watch Right... |
24,023 | 2021-07-05 00:00:00 UTC | 3 Warren Buffett Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-stocks-to-buy-in-july-2021-07-05 | null | null | Warren Buffett is back to his winning ways. His beloved Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) lagged well behind the S&P 500 in 2020. However, it's a much better story so far this year with Berkshire's shares up more than 20% -- well ahead of any of the major market indexes.
It wouldn't be a bad move at all fo... | AbbVie hopes to win European approval for Rinvoq in treating atopic dermatitis in Q3 after receiving a positive recommendation from the Committee for Medicinal Products for Human Use. AbbVie Buffett appeared to be a big fan of big pharma in 2020, buying shares of several large drugmakers. AbbVie (NYSE: ABBV) ranked as ... | Keith Speights owns shares of AbbVie, Amazon, Apple, and Berkshire Hathaway (B shares). AbbVie Buffett appeared to be a big fan of big pharma in 2020, buying shares of several large drugmakers. AbbVie (NYSE: ABBV) ranked as one of his top buys. | AbbVie Buffett appeared to be a big fan of big pharma in 2020, buying shares of several large drugmakers. AbbVie (NYSE: ABBV) ranked as one of his top buys. Berkshire has trimmed its position in AbbVie somewhat but still owns nearly 22.9 million shares. | My view is that AbbVie is Buffett's best dividend stock by far. AbbVie Buffett appeared to be a big fan of big pharma in 2020, buying shares of several large drugmakers. AbbVie (NYSE: ABBV) ranked as one of his top buys. |
24,024 | 2021-07-03 00:00:00 UTC | These COVID Therapies Appear to Be the Best and Worst at Treating New Variants | ABBV | https://www.nasdaq.com/articles/these-covid-therapies-appear-to-be-the-best-and-worst-at-treating-new-variants-2021-07-03 | null | null | Results were recently announced from a pre-clinical study comparing several of the leading COVID-19 antibody therapies. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli discuss which drugmakers were the biggest winners and losers in this comparison.
10 stocks ... | Brian Orelli: Yes, this was a pretty big study they tested monoclonal antibodies, treatments from Vir Biotechnology (NASDAQ: VIR), AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), Regeneron (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) Eli Lilly seems to be the big loser here. AbbVie's antibody combo had partial loss of act... | Brian Orelli: Yes, this was a pretty big study they tested monoclonal antibodies, treatments from Vir Biotechnology (NASDAQ: VIR), AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), Regeneron (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) Eli Lilly seems to be the big loser here. AbbVie's antibody combo had partial loss of act... | Brian Orelli: Yes, this was a pretty big study they tested monoclonal antibodies, treatments from Vir Biotechnology (NASDAQ: VIR), AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), Regeneron (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) Eli Lilly seems to be the big loser here. AbbVie's antibody combo had partial loss of act... | Brian Orelli: Yes, this was a pretty big study they tested monoclonal antibodies, treatments from Vir Biotechnology (NASDAQ: VIR), AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), Regeneron (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) Eli Lilly seems to be the big loser here. AbbVie's antibody combo had partial loss of act... |
24,025 | 2021-07-02 00:00:00 UTC | Got $400? 3 Fantastic Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/got-%24400-3-fantastic-dividend-stocks-to-buy-right-now-2021-07-02 | null | null | "Money is no object." You've likely heard the expression. The reality, though, is that money usually is an object -- namely because it's in relatively scarce quantity for most people.
Many investors don't have tens of thousands of dollars to invest each month. And many are jittery about putting the hard-earned money th... | AbbVie Calvin Coolidge was the U.S. president when AbbVie (NYSE: ABBV) first began paying dividends in 1924. You can currently buy one share of AbbVie for less than $115. AbbVie's dividend yield stands at 4.6%. | AbbVie Calvin Coolidge was the U.S. president when AbbVie (NYSE: ABBV) first began paying dividends in 1924. You can currently buy one share of AbbVie for less than $115. AbbVie's dividend yield stands at 4.6%. | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie and Innovative Industrial Properties. AbbVie Calvin Coolidge was the U.S. president when AbbVie (NYSE: ABBV) first began paying dividends in 1924. You can currently buy one share of AbbVie for less than $115. | You can currently buy one share of AbbVie for less than $115. AbbVie Calvin Coolidge was the U.S. president when AbbVie (NYSE: ABBV) first began paying dividends in 1924. AbbVie's dividend yield stands at 4.6%. |
24,026 | 2021-06-30 00:00:00 UTC | 5 High Dividend Stocks For Your July 2021 Watchlist | ABBV | https://www.nasdaq.com/articles/5-high-dividend-stocks-for-your-july-2021-watchlist-2021-06-30 | null | null | Is Now The Time To Add Stocks These High Paying Dividends Stocks To Your Portfolio?
Amidst the volatility seen in the stock market recently, many investors are considering safer investments like dividend stocks. As a result, the highest-paying dividend stocks in 2021 could have more room to grow right now. While that m... | With all that being said, here are some of the best dividend stocks to watch in thestock market today Best Dividend Stocks To Watch Right Now SoFi Weekly Income ETF (NYSEARCA: TGIF) Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) AGNC Investment Corp (NASDAQ: AGNC) SoFi Weekly Income ET... | With all that being said, here are some of the best dividend stocks to watch in thestock market today Best Dividend Stocks To Watch Right Now SoFi Weekly Income ETF (NYSEARCA: TGIF) Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) AGNC Investment Corp (NASDAQ: AGNC) SoFi Weekly Income ET... | With all that being said, here are some of the best dividend stocks to watch in thestock market today Best Dividend Stocks To Watch Right Now SoFi Weekly Income ETF (NYSEARCA: TGIF) Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) AGNC Investment Corp (NASDAQ: AGNC) SoFi Weekly Income ET... | With all that being said, here are some of the best dividend stocks to watch in thestock market today Best Dividend Stocks To Watch Right Now SoFi Weekly Income ETF (NYSEARCA: TGIF) Realty Income (NYSE: O) AbbVie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) AGNC Investment Corp (NASDAQ: AGNC) SoFi Weekly Income ET... |
24,027 | 2021-06-30 00:00:00 UTC | AbbVie: Is the Price Right for Long-Term Investment? | ABBV | https://www.nasdaq.com/articles/abbvie%3A-is-the-price-right-for-long-term-investment-2021-06-30 | null | null | As Foolish investors, we're seeking long-term success. That means paying attention not just to a company's operating fundamentals, but to how the market is valuing that company.
Imagine two investors, Anne and Barry. Both of them are interested in buying shares of a coffee company -- we'll call it Starfrancs. Both of t... | AbbVie's business is solid -- more on that below -- but as investors, we always want to leave ourselves with a margin of safety in case a company fails to meet our expectations. Let's take a look at pharma giant AbbVie (NYSE: ABBV), which is up 18% over the past year. AbbVie appears undervalued In an effort to determin... | We arrive at a fair value for shares of AbbVie of $125.55 a share, which is moderately higher than its current share price of $112.55. Let's take a look at pharma giant AbbVie (NYSE: ABBV), which is up 18% over the past year. AbbVie appears undervalued In an effort to determine the fair value of AbbVie's shares, we wil... | AbbVie appears undervalued In an effort to determine the fair value of AbbVie's shares, we will be using the discounted cash flow, or DCF, model. We arrive at a fair value for shares of AbbVie of $125.55 a share, which is moderately higher than its current share price of $112.55. Let's take a look at pharma giant AbbVi... | AbbVie appears undervalued In an effort to determine the fair value of AbbVie's shares, we will be using the discounted cash flow, or DCF, model. Further, AbbVie's two oncology drugs, Imbruvica and Venclexta, saw sales climb 7.3% year over year to a combined $1.7 billion in Q1 2021. Let's take a look at pharma giant Ab... |
24,028 | 2021-06-29 00:00:00 UTC | New York takes Teva, McKesson, others to trial over opioids | ABBV | https://www.nasdaq.com/articles/new-york-takes-teva-mckesson-others-to-trial-over-opioids-2021-06-29 | null | null | By Brendan Pierson
NEW YORK, June 29 (Reuters) - New York will take Teva Pharmaceutical Industries TEVA.TA and other companies, including the nation's largest drug distributors, to trial on Tuesday, seeking to hold them liable for fueling an opioid crisis that has caused nearly half a million U.S. deaths over a decade.... | It will pit state Attorney General Letitia James and Suffolk and Nassau Counties against drugmakers Teva, Endo International ENDP.O and Abbvie Inc ABBV.N, as well as drug distributors AmerisourceBergen Corp ABC.N, Cardinal Health Inc CAH.N and McKesson Corp MCK.N. The trial in Central Islip, New York, will mark the fir... | It will pit state Attorney General Letitia James and Suffolk and Nassau Counties against drugmakers Teva, Endo International ENDP.O and Abbvie Inc ABBV.N, as well as drug distributors AmerisourceBergen Corp ABC.N, Cardinal Health Inc CAH.N and McKesson Corp MCK.N. Another defendant in the case, drugmaker Johnson & John... | It will pit state Attorney General Letitia James and Suffolk and Nassau Counties against drugmakers Teva, Endo International ENDP.O and Abbvie Inc ABBV.N, as well as drug distributors AmerisourceBergen Corp ABC.N, Cardinal Health Inc CAH.N and McKesson Corp MCK.N. By Brendan Pierson NEW YORK, June 29 (Reuters) - New Yo... | It will pit state Attorney General Letitia James and Suffolk and Nassau Counties against drugmakers Teva, Endo International ENDP.O and Abbvie Inc ABBV.N, as well as drug distributors AmerisourceBergen Corp ABC.N, Cardinal Health Inc CAH.N and McKesson Corp MCK.N. Another defendant in the case, drugmaker Johnson & John... |
24,029 | 2021-06-29 00:00:00 UTC | Notable ETF Outflow Detected - XLV, PFE, ABBV, BMY | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-pfe-abbv-bmy-2021-06-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $138.5 million dollar outflow -- that's a 0.5% decrease week over week (from 222,520,000 to 221,4... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.1%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pri... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.1%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pri... |
24,030 | 2021-06-29 00:00:00 UTC | N.Y. jury urged to hold drugmakers liable for opioid crisis | ABBV | https://www.nasdaq.com/articles/n.y.-jury-urged-to-hold-drugmakers-liable-for-opioid-crisis-2021-06-29 | null | null | By Brendan Pierson
NEW YORK, June 29 (Reuters) - Teva Pharmaceutical Industries TEVA.TA, Endo International ENDP.O and Abbvie Inc's ABBV.N Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors Tuesday, urging them to hold the companies liable.
Jayne Conro... | By Brendan Pierson NEW YORK, June 29 (Reuters) - Teva Pharmaceutical Industries TEVA.TA, Endo International ENDP.O and Abbvie Inc's ABBV.N Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors Tuesday, urging them to hold the companies liable. The healthc... | By Brendan Pierson NEW YORK, June 29 (Reuters) - Teva Pharmaceutical Industries TEVA.TA, Endo International ENDP.O and Abbvie Inc's ABBV.N Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors Tuesday, urging them to hold the companies liable. Jayne Conro... | By Brendan Pierson NEW YORK, June 29 (Reuters) - Teva Pharmaceutical Industries TEVA.TA, Endo International ENDP.O and Abbvie Inc's ABBV.N Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors Tuesday, urging them to hold the companies liable. Jayne Conro... | By Brendan Pierson NEW YORK, June 29 (Reuters) - Teva Pharmaceutical Industries TEVA.TA, Endo International ENDP.O and Abbvie Inc's ABBV.N Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors Tuesday, urging them to hold the companies liable. The U.S. Ce... |
24,031 | 2021-06-28 00:00:00 UTC | These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval | ABBV | https://www.nasdaq.com/articles/these-3-high-dividend-stocks-have-cathie-woods-seal-of-approval-2021-06-28 | null | null | Cathie Wood has become an investing sensation in recent years. As the founder of the ARK Invest family of exchange-traded funds , amazing returns in 2020 gave her a reputation for finding little-followed high-growth companies early in their existence and riding them to big long-term gains. Investors in her ARK Innovati... | With a market capitalization of $200 billion, AbbVie is big enough to make strategic acquisitions of significant companies in key areas that Wood sees as having high growth prospects. AbbVie has already done considerable research and development on experimental cancer drugs using genomic analysis, and promising results... | AbbVie isn't a huge holding for Wood, but her ARK Genomic Revolution ETF (NYSEMKT: ARKG) has about $60 million invested in the pharma company. With a market capitalization of $200 billion, AbbVie is big enough to make strategic acquisitions of significant companies in key areas that Wood sees as having high growth pros... | AbbVie AbbVie (NYSE: ABBV) is perhaps the best-known dividend stock among the holdings of Cathie Wood's ETFs. AbbVie isn't a huge holding for Wood, but her ARK Genomic Revolution ETF (NYSEMKT: ARKG) has about $60 million invested in the pharma company. With a market capitalization of $200 billion, AbbVie is big enough ... | AbbVie AbbVie (NYSE: ABBV) is perhaps the best-known dividend stock among the holdings of Cathie Wood's ETFs. AbbVie isn't a huge holding for Wood, but her ARK Genomic Revolution ETF (NYSEMKT: ARKG) has about $60 million invested in the pharma company. With a market capitalization of $200 billion, AbbVie is big enough ... |
24,032 | 2021-06-26 00:00:00 UTC | J&J to pay $263 mln in New York opioid settlements, avoids trial | ABBV | https://www.nasdaq.com/articles/jj-to-pay-%24263-mln-in-new-york-opioid-settlements-avoids-trial-2021-06-26 | null | null | By Jonathan Stempel
NEW YORK, June 26 (Reuters) - Johnson & Johnson JNJ.N said on Saturday it will pay $263 million to resolve claims it fueled an opioid epidemic in New York state and two of its largest counties.
The settlements remove the drugmaker from a jury trial scheduled to begin on Tuesday on Long Island, where... | Drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA and several distributors are among the defendants. The settlements remove the drugmaker from a jury trial scheduled to begin on Tuesday on Long Island, where several big opioid makers and distributors are also defendants. J&J said the settlemen... | Drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA and several distributors are among the defendants. By Jonathan Stempel NEW YORK, June 26 (Reuters) - Johnson & Johnson JNJ.N said on Saturday it will pay $263 million to resolve claims it fueled an opioid epidemic in New York state and two of i... | Drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA and several distributors are among the defendants. By Jonathan Stempel NEW YORK, June 26 (Reuters) - Johnson & Johnson JNJ.N said on Saturday it will pay $263 million to resolve claims it fueled an opioid epidemic in New York state and two of i... | Drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA and several distributors are among the defendants. By Jonathan Stempel NEW YORK, June 26 (Reuters) - Johnson & Johnson JNJ.N said on Saturday it will pay $263 million to resolve claims it fueled an opioid epidemic in New York state and two of i... |
24,033 | 2021-06-25 00:00:00 UTC | Friday Sector Laggards: Energy, Healthcare | ABBV | https://www.nasdaq.com/articles/friday-sector-laggards%3A-energy-healthcare-2021-06-25 | null | null | The worst performing sector as of midday Friday is the Energy sector, higher by 0.2%. Within that group, APA Corp (Symbol: APA) and Devon Energy Corp. (Symbol: DVN) are two large stocks that are lagging, showing a loss of 1.1% and 0.6%, respectively. Among energy ETFs, one ETF following the sector is the Energy Select ... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Organon & Co (Symbol: OGN) are the most notable, showing a loss of 1.7% and 1.5%, respectively. AbbVie Inc, meanwhile, is up 7.68% year-to-date, and Organon & Co, is down 11.85% year-to-date. Combined, ABBV and OGN make up approximately 4.4% of the underlying... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Organon & Co (Symbol: OGN) are the most notable, showing a loss of 1.7% and 1.5%, respectively. AbbVie Inc, meanwhile, is up 7.68% year-to-date, and Organon & Co, is down 11.85% year-to-date. Combined, ABBV and OGN make up approximately 4.4% of the underlying... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Organon & Co (Symbol: OGN) are the most notable, showing a loss of 1.7% and 1.5%, respectively. AbbVie Inc, meanwhile, is up 7.68% year-to-date, and Organon & Co, is down 11.85% year-to-date. Combined, ABBV and OGN make up approximately 4.4% of the underlying... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Organon & Co (Symbol: OGN) are the most notable, showing a loss of 1.7% and 1.5%, respectively. AbbVie Inc, meanwhile, is up 7.68% year-to-date, and Organon & Co, is down 11.85% year-to-date. Combined, ABBV and OGN make up approximately 4.4% of the underlying... |
24,034 | 2021-06-25 00:00:00 UTC | Notable Friday Option Activity: PENN, ABBV, BAC | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-penn-abbv-bac-2021-06-25 | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Penn National Gaming Inc (Symbol: PENN), where a total of 21,776 contracts have traded so far, representing approximately 2.2 million underlying shares. That amounts to about 60.2% of PENN's average daily trading vol... | Particularly high volume was seen for the $110 strike put option expiring July 02, 2021, with 6,622 contracts trading so far today, representing approximately 662,200 underlying shares of ABBV. Below is a chart showing PENN's trailing twelve month trading history, with the $80 strike highlighted in orange: AbbVie Inc (... | Below is a chart showing PENN's trailing twelve month trading history, with the $80 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 39,419 contracts thus far today. That number of contracts represents approximately 3.9 million underlying shares, working out to a sizeable 60.1% of... | That number of contracts represents approximately 3.9 million underlying shares, working out to a sizeable 60.1% of ABBV's average daily trading volume over the past month, of 6.6 million shares. Below is a chart showing PENN's trailing twelve month trading history, with the $80 strike highlighted in orange: AbbVie Inc... | Particularly high volume was seen for the $110 strike put option expiring July 02, 2021, with 6,622 contracts trading so far today, representing approximately 662,200 underlying shares of ABBV. Below is a chart showing BAC's trailing twelve month trading history, with the $41 strike highlighted in orange: For the vario... |
24,035 | 2021-06-25 00:00:00 UTC | Forget Dogecoin: These Dogs of the Dow Are More Likely to Make You Rich | ABBV | https://www.nasdaq.com/articles/forget-dogecoin%3A-these-dogs-of-the-dow-are-more-likely-to-make-you-rich-2021-06-25 | null | null | There are many different investment strategies. Until recently, buying a cryptocurrency started as a joke wouldn't have been on the list. Yet, Dogecoin (CRYPTO: DOGE) continues to garner attention despite falling 65% from its high. It's entertaining, but those looking to build wealth might be barking up the wrong tree.... | That was second to AbbVie's Humira. Two of these -- Walgreens Boots Alliance (NASDAQ: WBA) and Merck (NYSE: MRK) -- could give your portfolio a lot more bite if left to compound over time. That scale means it doesn't grow very fast, but it does generate a lot of free cash flow -- more than $4.1 billion last year, even ... | That was second to AbbVie's Humira. Two of these -- Walgreens Boots Alliance (NASDAQ: WBA) and Merck (NYSE: MRK) -- could give your portfolio a lot more bite if left to compound over time. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | That was second to AbbVie's Humira. Merck Merck is a global pharmaceutical company best known for its asthma drug Singulair -- which went off-patent nearly a decade ago -- and cancer therapy Keytruda. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Merck & Co. wasn't... | That was second to AbbVie's Humira. Merck Merck is a global pharmaceutical company best known for its asthma drug Singulair -- which went off-patent nearly a decade ago -- and cancer therapy Keytruda. 10 stocks we like better than Merck & Co. |
24,036 | 2021-06-25 00:00:00 UTC | 3 High-Yield Stocks With Secure Payouts | ABBV | https://www.nasdaq.com/articles/3-high-yield-stocks-with-secure-payouts-2021-06-25 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The S&P 500 has nearly doubled off its bottom last year and has climbed to new all-time highs. As a result, it has become challenging for investors to identify reasonably valued stocks with high dividend yields. In the current environment, many high-dividen... | 9 Oil & Gas Stocks to Buy to Play Rising Energy Prices The high yielders that we believe have secure dividend payouts are: Altria Group (NYSE:MO) AbbVie Inc. (NYSE:ABBV) Enbridge Inc. (NYSE:ENB) Dividend Stocks: Altria Group (MO) MO) logo" width="300" height="169"> Source: Kristi Blokhin / Shutterstock.com Altria sells... | 9 Oil & Gas Stocks to Buy to Play Rising Energy Prices The high yielders that we believe have secure dividend payouts are: Altria Group (NYSE:MO) AbbVie Inc. (NYSE:ABBV) Enbridge Inc. (NYSE:ENB) Dividend Stocks: Altria Group (MO) MO) logo" width="300" height="169"> Source: Kristi Blokhin / Shutterstock.com Altria sells... | 9 Oil & Gas Stocks to Buy to Play Rising Energy Prices The high yielders that we believe have secure dividend payouts are: Altria Group (NYSE:MO) AbbVie Inc. (NYSE:ABBV) Enbridge Inc. (NYSE:ENB) Dividend Stocks: Altria Group (MO) MO) logo" width="300" height="169"> Source: Kristi Blokhin / Shutterstock.com Altria sells... | 9 Oil & Gas Stocks to Buy to Play Rising Energy Prices The high yielders that we believe have secure dividend payouts are: Altria Group (NYSE:MO) AbbVie Inc. (NYSE:ABBV) Enbridge Inc. (NYSE:ENB) Dividend Stocks: Altria Group (MO) MO) logo" width="300" height="169"> Source: Kristi Blokhin / Shutterstock.com Altria sells... |
24,037 | 2021-06-25 00:00:00 UTC | AbbVie Inc. (NYSE:ABBV) is Finding Balance between Dividends and Growth | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-nyse%3Aabbv-is-finding-balance-between-dividends-and-growth-2021-06-25 | null | null | By Goran Damchevski
This article was originally published on Simply Wall St News
AbbVie Inc. ( NYSE:ABBV ) is a large international pharmaceutical company.
AbbVie has six major focus areas including: immunology, oncology, neuroscience, eye care, virology, aesthetics. They have a strong and diversified pipeline of produ... | By Goran Damchevski This article was originally published on Simply Wall St News AbbVie Inc. ( NYSE:ABBV ) is a large international pharmaceutical company. AbbVie has six major focus areas including: immunology, oncology, neuroscience, eye care, virology, aesthetics. Analysts covering AbbVie are taking into account the... | By Goran Damchevski This article was originally published on Simply Wall St News AbbVie Inc. ( NYSE:ABBV ) is a large international pharmaceutical company. NYSE:ABBV Historic Dividend, June 2021 Payout Ratios Companies (usually) pay dividends out of their earnings. AbbVie has six major focus areas including: immunology... | Conclusion To summarize, shareholders should always check if AbbVie's dividends are affordable, that its dividend payments are relatively stable, and that it has decent prospects for growing its earnings and dividend. By Goran Damchevski This article was originally published on Simply Wall St News AbbVie Inc. ( NYSE:AB... | By Goran Damchevski This article was originally published on Simply Wall St News AbbVie Inc. ( NYSE:ABBV ) is a large international pharmaceutical company. AbbVie has six major focus areas including: immunology, oncology, neuroscience, eye care, virology, aesthetics. Analysts covering AbbVie are taking into account the... |
24,038 | 2021-06-23 00:00:00 UTC | Best Dividend Stocks To Buy Today? 3 To Watch Before July 2021 | ABBV | https://www.nasdaq.com/articles/best-dividend-stocks-to-buy-today-3-to-watch-before-july-2021-2021-06-23 | null | null | Check Out These 3 Top Dividend Stocks This Week
As the stock market recovers from a rough week of trading, some investors may be looking towards more defensive stocks now. In this case, dividend stocks would be among the viable plays now. Why? Simply put, this group of stocks can provide investors with recurring income... | Top Dividend Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Brookfield Renewable Partners (NYSE: BEP) Exxon Mobil Corporation (NYSE: XOM) AbbVie Inc. AbbVie is a health care company that delivers innovative medicines. ABBV stock has been up by over 30% since November. Since the company’s inception in 2013, AbbVi... | Top Dividend Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Brookfield Renewable Partners (NYSE: BEP) Exxon Mobil Corporation (NYSE: XOM) AbbVie Inc. AbbVie is a health care company that delivers innovative medicines. In it, AbbVie posted worldwide GAAP net revenues of $13.01 billion, an increase of 51% on a rep... | Top Dividend Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Brookfield Renewable Partners (NYSE: BEP) Exxon Mobil Corporation (NYSE: XOM) AbbVie Inc. AbbVie is a health care company that delivers innovative medicines. ABBV stock has been up by over 30% since November. Since the company’s inception in 2013, AbbVi... | Top Dividend Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Brookfield Renewable Partners (NYSE: BEP) Exxon Mobil Corporation (NYSE: XOM) AbbVie Inc. AbbVie is a health care company that delivers innovative medicines. ABBV stock has been up by over 30% since November. Since the company’s inception in 2013, AbbVi... |
24,039 | 2021-06-22 00:00:00 UTC | 2 Dividend Stocks That Could Be Paying You 10% Within 5 Years | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-that-could-be-paying-you-10-within-5-years-2021-06-22 | null | null | Income investors often shy away from high-yielding dividend stocks because of the risk. If a stock is paying 10% or more, it's not likely that the dividend will remain at that yield for too long. But if you are patient, it isn't impossible to earn back that high of a percentage of your original investment. Dividend gro... | Now that its acquisition of Botox-maker Allergan is complete, AbbVie's business is larger, more diverse, and in a better position to take advantage of a strong U.S. economy that is looking to get back to normal this year. Two top income stocks that you should consider today are AbbVie (NYSE: ABBV) and Enbridge (NYSE: E... | AbbVie Investors who buy shares of AbbVie today will earn $1.30 per share in quarterly dividends for each share they own. Two top income stocks that you should consider today are AbbVie (NYSE: ABBV) and Enbridge (NYSE: ENB). Now that its acquisition of Botox-maker Allergan is complete, AbbVie's business is larger, more... | AbbVie Investors who buy shares of AbbVie today will earn $1.30 per share in quarterly dividends for each share they own. AbbVie is a top income stock that is also a Dividend Aristocrat, and it can make for a safe investment that you can hold in your portfolio for many years. Two top income stocks that you should consi... | AbbVie is a top income stock that is also a Dividend Aristocrat, and it can make for a safe investment that you can hold in your portfolio for many years. Two top income stocks that you should consider today are AbbVie (NYSE: ABBV) and Enbridge (NYSE: ENB). AbbVie Investors who buy shares of AbbVie today will earn $1.3... |
24,040 | 2021-06-21 00:00:00 UTC | Does The Valuation Gap Between Merck Stock And Zoetis Make Sense? | ABBV | https://www.nasdaq.com/articles/does-the-valuation-gap-between-merck-stock-and-zoetis-make-sense-2021-06-22 | null | null | Zoetis stock (NYSE:ZTS) has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck’s stock (NYSE:MRK) has underperformed and gained only 26% of its value. Looking at valuation, Merck stock trades at about 4x trailing revenues, compared to ar... | For example, you’ll be surprised how counter-intuitive the stock valuation is for Hasbro vs. AbbVie. Keytruda, in particular, remains the biggest asset for Merck with sales of over $14 billion (roughly 30% of total revenues) in 2020, and it will likely continue to gain market share. Zoetis has seen steady top-line grow... | For example, you’ll be surprised how counter-intuitive the stock valuation is for Hasbro vs. AbbVie. The Net of It All It is evident that Zoetis’ historical revenue growth, operating margins, as well as operating income growth, all compare favorably with Merck. However, as we look forward, Merck will likely see steady ... | For example, you’ll be surprised how counter-intuitive the stock valuation is for Hasbro vs. AbbVie. While there are investor concerns over Merck’s diabetes portfolio of Januvia and Janumet (accounts for 12% of Merck’s total sales), which will likely see a slowdown in sales going forward, as it nears the end of the exc... | For example, you’ll be surprised how counter-intuitive the stock valuation is for Hasbro vs. AbbVie. However, as we look forward, we believe Merck stock will likely fare better than Zoetis because of its valuation, restructuring initiatives, and expansion of Keytruda. Revenue Growth Between 2018 and 2020, Merck’s reven... |
24,041 | 2021-06-21 00:00:00 UTC | Dual-antibody drugs effective against COVID-19 variants in animal study | ABBV | https://www.nasdaq.com/articles/dual-antibody-drugs-effective-against-covid-19-variants-in-animal-study-2021-06-21 | null | null | By Dania Nadeem
June 21 (Reuters) - COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study, the Washington University School of Medicine in St. Louis reported on Monday.
Antibodies are used to treat cases of COVID... | They also assessed the antibodies currently in clinical trials by AbbVie Inc ABBV.N, Vir and AstraZeneca AZN.L. By Dania Nadeem June 21 (Reuters) - COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study, the Washi... | They also assessed the antibodies currently in clinical trials by AbbVie Inc ABBV.N, Vir and AstraZeneca AZN.L. The U.S. Food and Drug Administration in April revoked the emergency use authorization of Eli Lilly's LLY.N single antibody therapy, bamlanivimab, saying there was increased circulation of variants resistant ... | They also assessed the antibodies currently in clinical trials by AbbVie Inc ABBV.N, Vir and AstraZeneca AZN.L. Other studies have previously shown that some antibody combination therapies remained potent against those emerging variants of the coronavirus that were resistant to single antibody therapies. The latest stu... | They also assessed the antibodies currently in clinical trials by AbbVie Inc ABBV.N, Vir and AstraZeneca AZN.L. By Dania Nadeem June 21 (Reuters) - COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study, the Washi... |
24,042 | 2021-06-21 00:00:00 UTC | Notable ETF Inflow Detected - XLV, ABBV, CVS, ANTM | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-abbv-cvs-antm-2021-06-21 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $272.0 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.8%, CVS Health Corporation (Symbol: CVS) is up about 1.5%, and Anthem Inc (Symbol: ANTM) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.8%, CVS Health Corporation (Symbol: CVS) is up about 1.5%, and Anthem Inc (Symbol: ANTM) is higher by about 1.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pri... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.8%, CVS Health Corporation (Symbol: CVS) is up about 1.5%, and Anthem Inc (Symbol: ANTM) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.8%, CVS Health Corporation (Symbol: CVS) is up about 1.5%, and Anthem Inc (Symbol: ANTM) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... |
24,043 | 2021-06-20 00:00:00 UTC | This Is Warren Buffett's Best Dividend Stock by Far | ABBV | https://www.nasdaq.com/articles/this-is-warren-buffetts-best-dividend-stock-by-far-2021-06-20 | null | null | It might seem that Warren Buffett doesn't like dividends. After all, Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) has never paid a dividend. Even with the company sitting on a cash stockpile of $145 billion, the legendary investor still hasn't hinted at any inclination to use some of the money to pay shareholders via... | Not only does AbbVie have a great track record of dividend increases, but it also offers a yield that just might make some income-seeking investors drool. A coronation on the way AbbVie (NYSE: ABBV) is only one dividend hike away from becoming a Dividend King. AbbVie has increased its dividend for 49 years in a row. | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Apple, Berkshire Hathaway (B shares), and Chevron. A coronation on the way AbbVie (NYSE: ABBV) is only one dividend hike away from becoming a Dividend King. AbbVie has increased its dividend for 49 years in a row. | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Apple, Berkshire Hathaway (B shares), and Chevron. A coronation on the way AbbVie (NYSE: ABBV) is only one dividend hike away from becoming a Dividend King. AbbVie has increased its dividend for 49 years in a row. | I believe that AbbVie is Buffett's best dividend stock, by far. With AbbVie's great story, you might expect that Buffett would be scooping up more shares of the healthcare stock. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Apple, Berkshire Hathaway (B shares), and C... |
24,044 | 2021-06-20 00:00:00 UTC | How This Pharma Company Can Benefit From Its Competitors | ABBV | https://www.nasdaq.com/articles/how-this-pharma-company-can-benefit-from-its-competitors-2021-06-20 | null | null | The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxoli... | A lengthening lead As a result of all this, go-to-market dates for JAK inhibitor-based products from Incyte, Eli Lilly (olumiant), Pfizer (abrocitinib), and AbbVie (rinvoq) as treatments for ADcould all be affected. The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administrat... | A lengthening lead As a result of all this, go-to-market dates for JAK inhibitor-based products from Incyte, Eli Lilly (olumiant), Pfizer (abrocitinib), and AbbVie (rinvoq) as treatments for ADcould all be affected. The FDA has recently placed increased focus on the potential side effects of JAK inhibitors such as ruxo... | A lengthening lead As a result of all this, go-to-market dates for JAK inhibitor-based products from Incyte, Eli Lilly (olumiant), Pfizer (abrocitinib), and AbbVie (rinvoq) as treatments for ADcould all be affected. The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administrat... | A lengthening lead As a result of all this, go-to-market dates for JAK inhibitor-based products from Incyte, Eli Lilly (olumiant), Pfizer (abrocitinib), and AbbVie (rinvoq) as treatments for ADcould all be affected. This makes for the second FDA delay involving a drug from Incyte. In April, its collaborative effort wit... |
24,045 | 2021-06-18 00:00:00 UTC | Daily Dividend Report: ABBV,BMY,UDR,EQR,MEI | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-abbvbmyudreqrmei-2021-06-18 | null | null | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable August 16, 2021 to stockholders of record at the close of business on July 15, 2021. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of t... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.30 per share. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least... |
24,046 | 2021-06-18 00:00:00 UTC | This Safe 5-Stock Healthcare Portfolio Yields 5.5% | ABBV | https://www.nasdaq.com/articles/this-safe-5-stock-healthcare-portfolio-yields-5.5-2021-06-18 | null | null | Healthcare--along with consumer staples ("buying stuff") and utilities ("keeping the lights on")--provide portfolio stability. Plus, they usually pay dividends, too!
Of the three safety sectors, healthcare is a steady growth market, too. Consider these stats from the Centers for Medicare & Medicaid Services:
National h... | Here, we'll examine five healthcare names that should keep your income portfolio in peak condition for years to come: AbbVie (ABBV) Dividend Yield: 4.5% AbbVie (ABBV) was famously spun off from Abbott Laboratories (ABT) at the start of 2013. And keeping in line with the pharmaceutical industry, ABBV has offered the sup... | Here, we'll examine five healthcare names that should keep your income portfolio in peak condition for years to come: AbbVie (ABBV) Dividend Yield: 4.5% AbbVie (ABBV) was famously spun off from Abbott Laboratories (ABT) at the start of 2013. And keeping in line with the pharmaceutical industry, ABBV has offered the sup... | Here, we'll examine five healthcare names that should keep your income portfolio in peak condition for years to come: AbbVie (ABBV) Dividend Yield: 4.5% AbbVie (ABBV) was famously spun off from Abbott Laboratories (ABT) at the start of 2013. And keeping in line with the pharmaceutical industry, ABBV has offered the sup... | Here, we'll examine five healthcare names that should keep your income portfolio in peak condition for years to come: AbbVie (ABBV) Dividend Yield: 4.5% AbbVie (ABBV) was famously spun off from Abbott Laboratories (ABT) at the start of 2013. And keeping in line with the pharmaceutical industry, ABBV has offered the sup... |
24,047 | 2021-06-18 00:00:00 UTC | Next Market Crash 101: 2 Top Growth Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/next-market-crash-101%3A-2-top-growth-stocks-to-buy-right-now-2021-06-18 | null | null | The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.
No matter how wor... | AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats. AbbVie Healthcare stock AbbVie (NYSE: ABBV) is another golden egg to have in your basket before the next market crash rolls around. As a spinoff of Abbott, AbbVie is... | There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both. Abb... | AbbVie Healthcare stock AbbVie (NYSE: ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats. As a spinoff of Abbott, AbbVie is... | AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. AbbVie Healthcare stock AbbVie (NYSE: ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent compan... |
24,048 | 2021-06-17 00:00:00 UTC | 2 Top Dividend Stocks You Can Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-top-dividend-stocks-you-can-buy-and-hold-forever-2021-06-17 | null | null | Dividend stocks can be a great source of passive income, and fortunately, there is no shortage of dividend-paying companies in the stock market. However, finding those whose businesses -- and payouts -- will remain intact through bull and bear markets can be a bit of a challenge. After all, many companies slash, or out... | AbbVie Dividend-seeking investors tend to look for companies with the ability to continue generating growing revenue and profits. Two that I think fall seamlessly into this group are healthcare giants AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie split from its former parent company, Abbott Laboratories, in Janu... | Two that I think fall seamlessly into this group are healthcare giants AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie split from its former parent company, Abbott Laboratories, in January 2013. When considering its run under Abbott, AbbVie has been around for several decades. | AbbVie has raised its payouts by 128.1% in the past five years, and the pharma company is likely to continue rewarding shareholders in this way for many years to come. Two that I think fall seamlessly into this group are healthcare giants AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie split from its former parent... | Two that I think fall seamlessly into this group are healthcare giants AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie split from its former parent company, Abbott Laboratories, in January 2013. When considering its run under Abbott, AbbVie has been around for several decades. |
24,049 | 2021-06-13 00:00:00 UTC | 3 Health Care Stocks To Watch Right Now | ABBV | https://www.nasdaq.com/articles/3-health-care-stocks-to-watch-right-now-2021-06-13 | null | null | Are These The Best Health Care Stocks To Buy This Week?
As the world continues to deal with the global coronavirus pandemic, investors could still be eyeing health care stocks. While they may not be the most active stocks in the stock market today, health care stocks would be a safe haven for some. After all, investors... | Earlier today, AbbVie announced that a four-year analysis of the drug showed longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease. Danelle James, the development lead on the drug said, “These latest data from the RESONATE-2 study further reinforce IMBRUVICA as a standard of c... | Top Health Care Stocks To Watch In June AbbVie Inc. (NYSE: ABBV) Moderna Inc. (NASDAQ: MRNA) Clover Health Investments Corporation (NASDAQ: CLOV) AbbVie Inc. Right off the bat, we will be looking at AbbVie Inc. For the uninitiated, the Illinois-based company is a major player in the biopharmaceutical industry now. Orig... | Top Health Care Stocks To Watch In June AbbVie Inc. (NYSE: ABBV) Moderna Inc. (NASDAQ: MRNA) Clover Health Investments Corporation (NASDAQ: CLOV) AbbVie Inc. Right off the bat, we will be looking at AbbVie Inc. For the uninitiated, the Illinois-based company is a major player in the biopharmaceutical industry now. Orig... | Top Health Care Stocks To Watch In June AbbVie Inc. (NYSE: ABBV) Moderna Inc. (NASDAQ: MRNA) Clover Health Investments Corporation (NASDAQ: CLOV) AbbVie Inc. Right off the bat, we will be looking at AbbVie Inc. For the uninitiated, the Illinois-based company is a major player in the biopharmaceutical industry now. Orig... |
24,050 | 2021-06-13 00:00:00 UTC | How Big Is Bristol Myers Squibb's Latest FDA Approval? | ABBV | https://www.nasdaq.com/articles/how-big-is-bristol-myers-squibbs-latest-fda-approval-2021-06-13 | null | null | Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis. In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli discuss just how big this FDA win is for Bristol Myers Squi... | There's three different TNF inhibitors; Remicade and Simponi from Johnson & Johnson, and Humira from AbbVie, and then Takeda and Johnson & Johnson also have other biologics that are approved for ulcerative colitis. Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. Bristol Myers Squibb (NYSE: BMY) ... | Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. There's three different TNF inhibitors; Remicade and Simponi from Johnson & Johnson, and Humira from AbbVie, and then Takeda and Johnson & Johnson also have other biologics that are approved for ulcerative colitis. In this Motley Fool Live video re... | There's three different TNF inhibitors; Remicade and Simponi from Johnson & Johnson, and Humira from AbbVie, and then Takeda and Johnson & Johnson also have other biologics that are approved for ulcerative colitis. Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. Bristol Myers Squibb (NYSE: BMY) ... | There's three different TNF inhibitors; Remicade and Simponi from Johnson & Johnson, and Humira from AbbVie, and then Takeda and Johnson & Johnson also have other biologics that are approved for ulcerative colitis. Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. See the 10 stocks *Stock Advisor ... |
24,051 | 2021-06-13 00:00:00 UTC | 3 Top Dividend Stocks to Buy in June | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-to-buy-in-june-2021-06-13 | null | null | If you're retired or approaching retirement, you'll definitely want to consider including high-quality dividend stocks in your portfolio. These stocks provide steady income that you can count on. Some of them even offer attractive growth prospects as well. Even if retirement isn't on the horizon for a long time to come... | AbbVie Arguably the most important thing to know about AbbVie's (NYSE: ABBV) pedigree is that it's a Dividend Aristocrat. You'll also be glad to know that AbbVie offers a juicy dividend yield of 4.5%. But how reliable will AbbVie's dividend be going forward? | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie Arguably the most important thing to know about AbbVie's (NYSE: ABBV) pedigree is that it's a Dividend Aristocrat. You'll also be glad to... | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie Arguably the most important thing to know about AbbVie's (NYSE: ABBV) pedigree is that it's a Dividend Aristocrat. You'll also be glad to... | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie Arguably the most important thing to know about AbbVie's (NYSE: ABBV) pedigree is that it's a Dividend Aristocrat. You'll also be glad to... |
24,052 | 2021-06-11 00:00:00 UTC | 3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market | ABBV | https://www.nasdaq.com/articles/3-absurdly-cheap-stocks-to-buy-in-a-ridiculously-expensive-market-2021-06-11 | null | null | Stocks are so expensive that revered value investor Benjamin Graham might be spinning in his grave. The S&P 500's cyclically adjusted price-to-earnings (CAPE) ratio is at its highest level since early 2000 -- right before the dot-com bubble burst. It's even higher than the level in 1929, the year of the infamous stock ... | AbbVie AbbVie's (NYSE: ABBV) shares currently trade at only nine times expected earnings. Why is AbbVie stock so cheap? Sure, AbbVie will experience a sales decline in a couple of years. | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie's (NYSE: ABBV) shares currently trade at only nine times expected earnings. Why is AbbVie stock so cheap? | See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, Pfizer, and Viatris Inc. AbbVie AbbVie's (NYSE: ABBV) shares currently trade at only nine times expected earnings. Why is AbbVie stock so cheap? | AbbVie AbbVie's (NYSE: ABBV) shares currently trade at only nine times expected earnings. Why is AbbVie stock so cheap? Sure, AbbVie will experience a sales decline in a couple of years. |
24,053 | 2021-06-11 00:00:00 UTC | AbbVie: 4-year Follow-up Analysis Of Phase 3 Venetoclax Trial Continues To Show Longer PFS In CLL | ABBV | https://www.nasdaq.com/articles/abbvie%3A-4-year-follow-up-analysis-of-phase-3-venetoclax-trial-continues-to-show-longer-pfs | null | null | (RTTNews) - AbbVie (ABBV) announced Friday results from a four-year follow-up analysis of the Phase 3 CLL14 trial. The new data shows that AbbVie's VENCLYXTO/VENCLEXTA fixed duration combination demonstrates sustained progression-free survival or PFS in chronic lymphocytic leukemia or CLL patients after three years off... | The new data shows that AbbVie's VENCLYXTO/VENCLEXTA fixed duration combination demonstrates sustained progression-free survival or PFS in chronic lymphocytic leukemia or CLL patients after three years off treatment. (RTTNews) - AbbVie (ABBV) announced Friday results from a four-year follow-up analysis of the Phase 3 C... | The new data shows that AbbVie's VENCLYXTO/VENCLEXTA fixed duration combination demonstrates sustained progression-free survival or PFS in chronic lymphocytic leukemia or CLL patients after three years off treatment. Mohamed Zaki, vice president and head, global oncology development, AbbVie, "The CLL14 trial results ob... | The new data shows that AbbVie's VENCLYXTO/VENCLEXTA fixed duration combination demonstrates sustained progression-free survival or PFS in chronic lymphocytic leukemia or CLL patients after three years off treatment. Mohamed Zaki, vice president and head, global oncology development, AbbVie, "The CLL14 trial results ob... | The new data shows that AbbVie's VENCLYXTO/VENCLEXTA fixed duration combination demonstrates sustained progression-free survival or PFS in chronic lymphocytic leukemia or CLL patients after three years off treatment. Mohamed Zaki, vice president and head, global oncology development, AbbVie, "The CLL14 trial results ob... |
24,054 | 2021-06-11 00:00:00 UTC | iShares Russell 1000 ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-etf-experiences-big-outflow-2021-06-11 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $119.2 million dollar outflow -- that's a 0.4% decrease week over week (from 123,250,000 to 122,750,000). Among t... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Walmart Inc (Symbol: WMT) is up about 0.2%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.5%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Walmart Inc (Symbol: WMT) is up about 0.2%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.5%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Walmart Inc (Symbol: WMT) is up about 0.2%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of IWB, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Walmart Inc (Symbol: WMT) is up about 0.2%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
24,055 | 2021-06-10 00:00:00 UTC | Notable Thursday Option Activity: MO, AMC, ABBV | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-mo-amc-abbv-2021-06-10 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Altria Group Inc (Symbol: MO), where a total of 30,993 contracts have traded so far, representing approximately 3.1 million underlying shares. That amounts to about 49.1% of MO's average daily trading volume ove... | Especially high volume was seen for the $117 strike call option expiring June 11, 2021, with 7,513 contracts trading so far today, representing approximately 751,300 underlying shares of ABBV. Below is a chart showing AMC's trailing twelve month trading history, with the $40 strike highlighted in orange: And AbbVie Inc... | That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 47.3% of ABBV's average daily trading volume over the past month, of 7.1 million shares. Below is a chart showing AMC's trailing twelve month trading history, with the $40 strike highlighted in orange: And AbbVie ... | Below is a chart showing AMC's trailing twelve month trading history, with the $40 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,546 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 47.3%... | Especially high volume was seen for the $117 strike call option expiring June 11, 2021, with 7,513 contracts trading so far today, representing approximately 751,300 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $117 strike highlighted in orange: For the vari... |
24,056 | 2021-06-10 00:00:00 UTC | 2 Top Healthcare Stocks to Buy in a Market Crash | ABBV | https://www.nasdaq.com/articles/2-top-healthcare-stocks-to-buy-in-a-market-crash-2021-06-10 | null | null | Are you ready for the next market crash? You had better be because the next one is always just around the corner.
Short-term minded investors tend to dump their stocks at the first sign of a market crash and it's a surefire way to underperform over the long run. Successful investors, though, know that dips, corrections... | AbbVie is a top stock for long-term investors to buy on the dips because the company keeps coming up with ways to extend market exclusivity for treatments that are both popular and expensive. Take your pick Steady sales of Humira coupled with a product line dotted with rising stars have allowed AbbVie to triple its div... | Products from AbbVie (NYSE: ABBV) and subscriptions to Veeva Systems (NYSE: VEEV) generate strong cash flows in good economic times and bad. In 2013, Abbott spun AbbVie out into a separate company to shield its relatively steady cash flows from incoming biosimilar competition for Humira. Take your pick Steady sales of ... | Products from AbbVie (NYSE: ABBV) and subscriptions to Veeva Systems (NYSE: VEEV) generate strong cash flows in good economic times and bad. AbbVie is a top stock for long-term investors to buy on the dips because the company keeps coming up with ways to extend market exclusivity for treatments that are both popular an... | AbbVie You might not realize it, but new drug patents are usually good for just 25 years. Botox, Humira, and the rest of AbbVie's product lineup delivered a whopping $17.8 billion in free cash flow to AbbVie's bottom line over the past year. Products from AbbVie (NYSE: ABBV) and subscriptions to Veeva Systems (NYSE: VE... |
24,057 | 2021-06-09 00:00:00 UTC | 2 High-Yield Dividend Stocks for 2021 | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-for-2021-2021-06-09 | null | null | John D. Rockefeller once said, "Do you know the only thing that gives me pleasure? It's to see my dividends coming in." But not all dividends are created equal. High-yielding dividend stocks may not always be a safe investment, as an unusually high yield might signal a company in trouble or an impending dividend cut.
S... | Humira will lose patent protection here in the U.S in 2023, and given the drug's superstar status, investors might be concerned about whether AbbVie can sustain revenues and if the dividend is safe. Beyond Humira, AbbVie has a whole host of products in its portfolio that will keep revenue steady: Skyrizi (for plaque ps... | Still, there are a few safe and attractive high-yield dividend stocks in today's market, two of them being AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbVie AbbVie arrived on the scene back in 2013 after being spun off from Abbott Laboratories. Humira will lose patent protection here in the U.S in 2023, and given the ... | Humira will lose patent protection here in the U.S in 2023, and given the drug's superstar status, investors might be concerned about whether AbbVie can sustain revenues and if the dividend is safe. Still, there are a few safe and attractive high-yield dividend stocks in today's market, two of them being AbbVie (NYSE: ... | Even though it's only been around for eight years, AbbVie is a Dividend Aristocrat -- its time as part of Abbott Labs counts toward its consistently increasing payouts for more than 25 years. Still, there are a few safe and attractive high-yield dividend stocks in today's market, two of them being AbbVie (NYSE: ABBV) a... |
24,058 | 2021-06-08 00:00:00 UTC | AbbVie To Present At The Goldman Sachs Global Healthcare Conference; Webcast At 9:40 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-the-goldman-sachs-global-healthcare-conference-webcast-at-9%3A40-am-et | null | null | (RTTNews) - AbbVie (ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference.
The event is scheduled to begin at 9:40 AM ET on June 8, 2021.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are... | (RTTNews) - AbbVie (ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily re... | (RTTNews) - AbbVie (ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily re... | (RTTNews) - AbbVie (ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily re... | (RTTNews) - AbbVie (ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily re... |
24,059 | 2021-06-07 00:00:00 UTC | AbbVie Says Health Canada OKs RINVOQ For Adults With Active Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie-says-health-canada-oks-rinvoq-for-adults-with-active-psoriatic-arthritis-2021-06-07 | null | null | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) said Monday that Canadian regulator Health Canada has approved RINVOQ for the treatment of adults with active psoriatic arthritis or PsA.
RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor was administered to adults with active Ps... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) said Monday that Canadian regulator Health Canada has approved RINVOQ for the treatment of adults with active psoriatic arthritis or PsA. RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor was administered to adults with active Ps... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) said Monday that Canadian regulator Health Canada has approved RINVOQ for the treatment of adults with active psoriatic arthritis or PsA. RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor was administered to adults with active Ps... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) said Monday that Canadian regulator Health Canada has approved RINVOQ for the treatment of adults with active psoriatic arthritis or PsA. The company said the approval is backed by efficacy and safety data of two pivotal Phase 3 studies and that the safety profile of ... | (RTTNews) - Biopharmaceutical company AbbVie (ABBV) said Monday that Canadian regulator Health Canada has approved RINVOQ for the treatment of adults with active psoriatic arthritis or PsA. RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor was administered to adults with active Ps... |
24,060 | 2021-06-03 00:00:00 UTC | IWV, NFLX, CRM, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iwv-nflx-crm-abbv%3A-large-inflows-detected-at-etf-2021-06-03 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $125.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 46,150,000 to 46... | Among the largest underlying components of IWV, in trading today Netflix Inc (Symbol: NFLX) is down about 1.6%, Salesforce.com Inc (Symbol: CRM) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWV, in trading today Netflix Inc (Symbol: NFLX) is down about 1.6%, Salesforce.com Inc (Symbol: CRM) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWV, in trading today Netflix Inc (Symbol: NFLX) is down about 1.6%, Salesforce.com Inc (Symbol: CRM) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of IWV, in trading today Netflix Inc (Symbol: NFLX) is down about 1.6%, Salesforce.com Inc (Symbol: CRM) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
24,061 | 2021-06-02 00:00:00 UTC | Senate Finance Committee launches probe into AbbVie's tax practices | ABBV | https://www.nasdaq.com/articles/senate-finance-committee-launches-probe-into-abbvies-tax-practices-2021-06-02 | null | null | June 2 (Reuters) - Senate Finance Committee Chairman Ron Wyden has launched an investigation into AbbVie's ABBV.N international tax practices, saying the drugmaker has avoided paying taxes on U.S. prescription drug sales by shifting its profit overseas.
In a letter addressed to AbbVie's chief executive officer, Richard... | June 2 (Reuters) - Senate Finance Committee Chairman Ron Wyden has launched an investigation into AbbVie's ABBV.N international tax practices, saying the drugmaker has avoided paying taxes on U.S. prescription drug sales by shifting its profit overseas. In a letter addressed to AbbVie's chief executive officer, Richard... | In a letter addressed to AbbVie's chief executive officer, Richard Gonzalez, on Wednesday, Wyden noted that the company has consistently reported a net loss in the United States and net income overseas, despite being headquartered in the country. Wyden said in the letter that AbbVie reported a domestic pretax loss of $... | June 2 (Reuters) - Senate Finance Committee Chairman Ron Wyden has launched an investigation into AbbVie's ABBV.N international tax practices, saying the drugmaker has avoided paying taxes on U.S. prescription drug sales by shifting its profit overseas. "It appears that AbbVie shifts profits offshore while reporting a ... | AbbVie is already under scrutiny for its drug pricing practices, which U.S. lawmakers questioned last month, accusing the company of profiting from Americans by repeatedly raising U.S. prices on its widely-used rheumatoid arthritis drug, Humira, while cutting prices abroad. "It appears that AbbVie shifts profits offsho... |
24,062 | 2021-06-02 00:00:00 UTC | AbbVie Announces Positive Results From Late-stage Study Of Crohn's Disease Treatment | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-results-from-late-stage-study-of-crohns-disease-treatment-2021 | null | null | (RTTNews) - AbbVie (ABBV) Wednesday announced positive results from a late-stage study of its treatment for Crohn's disease.
AbbVie announced that risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease.
In... | (RTTNews) - AbbVie (ABBV) Wednesday announced positive results from a late-stage study of its treatment for Crohn's disease. AbbVie announced that risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. Si... | (RTTNews) - AbbVie (ABBV) Wednesday announced positive results from a late-stage study of its treatment for Crohn's disease. AbbVie announced that risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. In... | (RTTNews) - AbbVie (ABBV) Wednesday announced positive results from a late-stage study of its treatment for Crohn's disease. AbbVie announced that risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. In... | (RTTNews) - AbbVie (ABBV) Wednesday announced positive results from a late-stage study of its treatment for Crohn's disease. AbbVie announced that risankizumab 360 mg achieved the co-primary endpoints of endoscopic response and clinical remission at one year in adult patients with moderate to severe Crohn's disease. Th... |
24,063 | 2021-06-01 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2021-06-01 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Church & Dwight Co Inc (Symbol: CHD) $85.73 $94.00 9.65% Donaldson Co. Inc. (Symbol: DCI) $61.59 $65.75 6.75% AbbVie Inc (Symbol: ABBV) $113.20 $120.21 6.20% Target Corp (Symbol: TGT) $226.92 $239.47 5.53% National Fuel Gas Co. (Symbol: NFG) $51.89 $54.50 5.03% The average 12-month analyst targets are only targets for ... | Church & Dwight Co Inc (Symbol: CHD) $85.73 $94.00 9.65% Donaldson Co. Inc. (Symbol: DCI) $61.59 $65.75 6.75% AbbVie Inc (Symbol: ABBV) $113.20 $120.21 6.20% Target Corp (Symbol: TGT) $226.92 $239.47 5.53% National Fuel Gas Co. (Symbol: NFG) $51.89 $54.50 5.03% The average 12-month analyst targets are only targets for ... | Church & Dwight Co Inc (Symbol: CHD) $85.73 $94.00 9.65% Donaldson Co. Inc. (Symbol: DCI) $61.59 $65.75 6.75% AbbVie Inc (Symbol: ABBV) $113.20 $120.21 6.20% Target Corp (Symbol: TGT) $226.92 $239.47 5.53% National Fuel Gas Co. (Symbol: NFG) $51.89 $54.50 5.03% The average 12-month analyst targets are only targets for ... | Church & Dwight Co Inc (Symbol: CHD) $85.73 $94.00 9.65% Donaldson Co. Inc. (Symbol: DCI) $61.59 $65.75 6.75% AbbVie Inc (Symbol: ABBV) $113.20 $120.21 6.20% Target Corp (Symbol: TGT) $226.92 $239.47 5.53% National Fuel Gas Co. (Symbol: NFG) $51.89 $54.50 5.03% The average 12-month analyst targets are only targets for ... |
24,064 | 2021-05-31 00:00:00 UTC | 6 Top Dividend Stocks To Watch For Your Retirement Plan | ABBV | https://www.nasdaq.com/articles/6-top-dividend-stocks-to-watch-for-your-retirement-plan-2021-05-31 | null | null | Are These The Best Dividend Stocks To Help You Build Retirement Wealth?
There’s no question that we all need income to live on, and that’s where dividend stocks come into the picture. And the great news here is, you don’t need to have a lot of money to begin investing in the stock market. If you don’t believe me, just ... | Top Dividend Stocks For Your June Watchlist Innovative Industrial Properties Inc. (NYSE: IIPR) Realty Income Corporation (NYSE: O) Lumen Technologies (NYSE: LUMN) Coca-Cola Co. (NYSE: KO) Abbvie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) Innovative Industrial Properties First up, we have Innovative Industrial Pr... | Top Dividend Stocks For Your June Watchlist Innovative Industrial Properties Inc. (NYSE: IIPR) Realty Income Corporation (NYSE: O) Lumen Technologies (NYSE: LUMN) Coca-Cola Co. (NYSE: KO) Abbvie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) Innovative Industrial Properties First up, we have Innovative Industrial Pr... | Top Dividend Stocks For Your June Watchlist Innovative Industrial Properties Inc. (NYSE: IIPR) Realty Income Corporation (NYSE: O) Lumen Technologies (NYSE: LUMN) Coca-Cola Co. (NYSE: KO) Abbvie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) Innovative Industrial Properties First up, we have Innovative Industrial Pr... | Top Dividend Stocks For Your June Watchlist Innovative Industrial Properties Inc. (NYSE: IIPR) Realty Income Corporation (NYSE: O) Lumen Technologies (NYSE: LUMN) Coca-Cola Co. (NYSE: KO) Abbvie Inc. (NYSE: ABBV) Chevron Corporation (NYSE: CVX) Innovative Industrial Properties First up, we have Innovative Industrial Pr... |
24,065 | 2021-05-30 00:00:00 UTC | Is Viatris a Good Stock to Buy for 2021? | ABBV | https://www.nasdaq.com/articles/is-viatris-a-good-stock-to-buy-for-2021-2021-05-30 | null | null | The volatility that's shaken the markets over the past few weeks has woken some investors up, sending them out shopping to look for cheap stocks. Finding quality, inexpensive stocks can be difficult -- but there are bargains out there.
One cheap stock worth considering is drugmaker Viatris (NASDAQ: VTRS). It trades at ... | Some notable biosimilars in this pipeline include analogues to AbbVie's Humira and Amgen's Enbrel. If the company sustains this level of free cash flow for the entire year, bringing in an estimated $3.2 billion, management can definitely meet its debt reduction goals by 2023. Humira has been the world's best-selling dr... | Some notable biosimilars in this pipeline include analogues to AbbVie's Humira and Amgen's Enbrel. Viatris in the first quarter showed that it is a cash cow, bringing in $4.4 billion in revenue and almost $800 million in free cash flow. If the company sustains this level of free cash flow for the entire year, bringing ... | Some notable biosimilars in this pipeline include analogues to AbbVie's Humira and Amgen's Enbrel. While it is a legacy-brand drug that faces competition from generic alternatives, Viagra nonetheless remains the most distributed medication for this condition and is expected to account for 27% of market share, bringing ... | Some notable biosimilars in this pipeline include analogues to AbbVie's Humira and Amgen's Enbrel. Let me show you why you might want to consider buying Viatris stock this year. Some of its most popular products include both generics and legacy-branded drugs. |
24,066 | 2021-05-29 00:00:00 UTC | Got $5,000? Buy These 2 Stocks Instead of Dogecoin | ABBV | https://www.nasdaq.com/articles/got-%245000-buy-these-2-stocks-instead-of-dogecoin-2021-05-29 | null | null | If you love lottery tickets, Dogecoin (CRYPTO: DOGE) is right up your alley. Especially in recent months, the adorably puckish cryptocurrency is a dramedy of rocketship gains and cartoonishly steep losses. But its volatility and unpredictability mean that it isn't a great investment for everyone.
The issue with Dogecoi... | While some people might try to argue that Dogecoin's return is also linked to holding it for a long time, most investors will probably find it much less stressful to buy AbbVie's stock instead. AbbVie AbbVie (NYSE: ABBV) is a particularly appealing option for investors who like to see cash flows from their holdings. As... | See the 10 stocks *Stock Advisor returns as of May 11, 2021 Alex Carchidi owns shares of AbbVie. AbbVie AbbVie (NYSE: ABBV) is a particularly appealing option for investors who like to see cash flows from their holdings. As a pharma giant with more than $50 billion in trailing revenue and $24.53 billion in earnings bef... | While some people might try to argue that Dogecoin's return is also linked to holding it for a long time, most investors will probably find it much less stressful to buy AbbVie's stock instead. AbbVie AbbVie (NYSE: ABBV) is a particularly appealing option for investors who like to see cash flows from their holdings. As... | While some people might try to argue that Dogecoin's return is also linked to holding it for a long time, most investors will probably find it much less stressful to buy AbbVie's stock instead. AbbVie AbbVie (NYSE: ABBV) is a particularly appealing option for investors who like to see cash flows from their holdings. As... |
24,067 | 2021-05-27 00:00:00 UTC | 2 Stocks to Buy With Dividends Yielding More Than 3% | ABBV | https://www.nasdaq.com/articles/2-stocks-to-buy-with-dividends-yielding-more-than-3-2021-05-27 | null | null | The increasing volatility we're seeing in stocks signals to some we may be approaching a market peak. Even with the economy chugging back to life toward a summer of near-normalcy in the U.S., there are indications investors may want to be a bit more defensive.
Buying dividend-paying stocks is a smart strategy regardles... | AbbVie The brilliance of an investment in pharmaceutical giant AbbVie (NYSE: ABBV) has been the growth of its rheumatoid arthritis treatment, Humira, the global best-selling drug for the past two decades. Still the single biggest contributor to the pharma company's revenue, it generated $19.8 billion for AbbVie in 2020... | AbbVie The brilliance of an investment in pharmaceutical giant AbbVie (NYSE: ABBV) has been the growth of its rheumatoid arthritis treatment, Humira, the global best-selling drug for the past two decades. Still the single biggest contributor to the pharma company's revenue, it generated $19.8 billion for AbbVie in 2020... | AbbVie The brilliance of an investment in pharmaceutical giant AbbVie (NYSE: ABBV) has been the growth of its rheumatoid arthritis treatment, Humira, the global best-selling drug for the past two decades. Still the single biggest contributor to the pharma company's revenue, it generated $19.8 billion for AbbVie in 2020... | * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie The brilliance of an investment in pharmaceutical giant AbbVie (NYSE: ABBV) has been the growth of its rheumatoid arthritis treatment, Humira, the global best-selling drug for ... |
24,068 | 2021-05-27 00:00:00 UTC | 5 Stocks Warren Buffett Is Selling That You Should Be Buying | ABBV | https://www.nasdaq.com/articles/5-stocks-warren-buffett-is-selling-that-you-should-be-buying-2021-05-27 | null | null | When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett speaks, Wall Street and retail investors listen. That's because Berkshire Hathaway's share price has risen by an annual average of 20% since the mid-1960s under his leadership.
Last week, the Oracle of Omaha's company filed a Form 13F with the Securi... | AbbVie High-yield drug stock AbbVie (NYSE: ABBV) was yet another healthcare stock to get reduced in the first quarter. There's no question that AbbVie will face challenges in its future. This well-known anti-inflammatory brought in $19.8 billion in sales in 2020 and accounted for about 43% of AbbVie's total revenue. | AbbVie High-yield drug stock AbbVie (NYSE: ABBV) was yet another healthcare stock to get reduced in the first quarter. There's no question that AbbVie will face challenges in its future. This well-known anti-inflammatory brought in $19.8 billion in sales in 2020 and accounted for about 43% of AbbVie's total revenue. | AbbVie High-yield drug stock AbbVie (NYSE: ABBV) was yet another healthcare stock to get reduced in the first quarter. There's no question that AbbVie will face challenges in its future. This well-known anti-inflammatory brought in $19.8 billion in sales in 2020 and accounted for about 43% of AbbVie's total revenue. | AbbVie High-yield drug stock AbbVie (NYSE: ABBV) was yet another healthcare stock to get reduced in the first quarter. There's no question that AbbVie will face challenges in its future. This well-known anti-inflammatory brought in $19.8 billion in sales in 2020 and accounted for about 43% of AbbVie's total revenue. |
24,069 | 2021-05-26 00:00:00 UTC | Notable ETF Inflow Detected - ESGU, NEE, CRM, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-esgu-nee-crm-abbv-2021-05-26 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG Aware MSCI USA ETF (Symbol: ESGU) where we have detected an approximate $157.9 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 180,150,0... | Among the largest underlying components of ESGU, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.2%, Salesforce.com Inc (Symbol: CRM) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one ye... | Among the largest underlying components of ESGU, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.2%, Salesforce.com Inc (Symbol: CRM) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one ye... | Among the largest underlying components of ESGU, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.2%, Salesforce.com Inc (Symbol: CRM) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... | Among the largest underlying components of ESGU, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.2%, Salesforce.com Inc (Symbol: CRM) is up about 0.6%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... |
24,070 | 2021-05-26 00:00:00 UTC | 5 Reasons Not to Sell During a Market Crash | ABBV | https://www.nasdaq.com/articles/5-reasons-not-to-sell-during-a-market-crash-2021-05-26 | null | null | When volatility surges and chaos reigns in the market, the temptation to sell your stocks is quite acute. Especially if you love to get minute-by-minute price updates from your phone, seeing a torrent of notifications about your cherished stocks plummeting gets old very quickly. All the while, the allure of a rapid esc... | If that doesn't seem right to you, take a look at AbbVie's (NYSE: ABBV) price behavior during and after the 2020 collapse. ABBV data by YCharts 3. In the case of a strong dividend stock like AbbVie, you could be missing out on a yield of around 4.5% per year, which grows quite quickly over time. | See the 10 stocks Stock Advisor returns as of 2/1/20 Alex Carchidi owns shares of AbbVie. If that doesn't seem right to you, take a look at AbbVie's (NYSE: ABBV) price behavior during and after the 2020 collapse. ABBV data by YCharts 3. | If that doesn't seem right to you, take a look at AbbVie's (NYSE: ABBV) price behavior during and after the 2020 collapse. ABBV data by YCharts 3. In the case of a strong dividend stock like AbbVie, you could be missing out on a yield of around 4.5% per year, which grows quite quickly over time. | In the case of a strong dividend stock like AbbVie, you could be missing out on a yield of around 4.5% per year, which grows quite quickly over time. If that doesn't seem right to you, take a look at AbbVie's (NYSE: ABBV) price behavior during and after the 2020 collapse. ABBV data by YCharts 3. |
24,071 | 2021-05-26 00:00:00 UTC | 2 Smart Stocks to Pick During a Market Correction | ABBV | https://www.nasdaq.com/articles/2-smart-stocks-to-pick-during-a-market-correction-2021-05-26 | null | null | The U.S. equity market has been highly volatile in the past few days. The April 2021 consumer price index (CPI) came in at 4.2 (a metric used to gauge inflation), which was far higher than the Federal Reserve's average inflation target of 2%. This made the market justifiably jittery about the possibility of tightening ... | Johnson & Johnson, Teva Pharmaceuticals (NYSE: TEVA), AbbVie (NYSE: ABBV), and Endo International (NASDAQ: ENDP) are currently facing a trial wherein several California counties have sued the businesses for $50 billion for their role in the U.S. opioid epidemic. In an April 27–28 Federal Open Market Committee meeting, ... | Johnson & Johnson, Teva Pharmaceuticals (NYSE: TEVA), AbbVie (NYSE: ABBV), and Endo International (NASDAQ: ENDP) are currently facing a trial wherein several California counties have sued the businesses for $50 billion for their role in the U.S. opioid epidemic. The company reported a non-GAAP net income of $1.05 billi... | Johnson & Johnson, Teva Pharmaceuticals (NYSE: TEVA), AbbVie (NYSE: ABBV), and Endo International (NASDAQ: ENDP) are currently facing a trial wherein several California counties have sued the businesses for $50 billion for their role in the U.S. opioid epidemic. However, these uncertain times can also prove to be an at... | Johnson & Johnson, Teva Pharmaceuticals (NYSE: TEVA), AbbVie (NYSE: ABBV), and Endo International (NASDAQ: ENDP) are currently facing a trial wherein several California counties have sued the businesses for $50 billion for their role in the U.S. opioid epidemic. However, these uncertain times can also prove to be an at... |
24,072 | 2021-05-25 00:00:00 UTC | Roche : EU Oks Venclyxto-based Combinations For Adults With Newly Diagnosed Acute Myeloid Leukaemia | ABBV | https://www.nasdaq.com/articles/roche-%3A-eu-oks-venclyxto-based-combinations-for-adults-with-newly-diagnosed-acute-myeloid | null | null | (RTTNews) - The European Commission has approved Venclyxto or venetoclax in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia or AML who are ineligible for intensive chemotherapy, AbbVie (ABBV) and Roche (RHHBY) said in ... | (RTTNews) - The European Commission has approved Venclyxto or venetoclax in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia or AML who are ineligible for intensive chemotherapy, AbbVie (ABBV) and Roche (RHHBY) said in ... | (RTTNews) - The European Commission has approved Venclyxto or venetoclax in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia or AML who are ineligible for intensive chemotherapy, AbbVie (ABBV) and Roche (RHHBY) said in ... | (RTTNews) - The European Commission has approved Venclyxto or venetoclax in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia or AML who are ineligible for intensive chemotherapy, AbbVie (ABBV) and Roche (RHHBY) said in ... | (RTTNews) - The European Commission has approved Venclyxto or venetoclax in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia or AML who are ineligible for intensive chemotherapy, AbbVie (ABBV) and Roche (RHHBY) said in ... |
24,073 | 2021-05-25 00:00:00 UTC | 3 Strong Stocks for Your Income Tax Return | ABBV | https://www.nasdaq.com/articles/3-strong-stocks-for-your-income-tax-return-2021-05-25 | null | null | Congratulations on getting some money back in your income tax return! Now, put it to work. The following medical stocks are an ideal place to invest that cash because of their consistent total returns.
Owens & Minor (NYSE: OMI), AbbVie (NYSE: ABBV), and PerkinElmer (NYSE: PKI) all have diverse revenue streams that make... | On Tuesday, a report by the House Oversight and Reform Committee found that AbbVie had inflated its prices for Humira, which is used to treat rheumatoid arthritis and other autoimmune diseases, and for Imbruvica, which is a therapy for mantle cell lymphoma and other cancers. The reality is AbbVie is a big, diversified ... | Owens & Minor (NYSE: OMI), AbbVie (NYSE: ABBV), and PerkinElmer (NYSE: PKI) all have diverse revenue streams that make them less susceptible to an economic downturn. AbbVie's size, scope will help it push past Humira patent cliff AbbVie's stock is up more than 25% over the past 12 months and more than 9% this year. On ... | Owens & Minor (NYSE: OMI), AbbVie (NYSE: ABBV), and PerkinElmer (NYSE: PKI) all have diverse revenue streams that make them less susceptible to an economic downturn. AbbVie's size, scope will help it push past Humira patent cliff AbbVie's stock is up more than 25% over the past 12 months and more than 9% this year. On ... | Owens & Minor (NYSE: OMI), AbbVie (NYSE: ABBV), and PerkinElmer (NYSE: PKI) all have diverse revenue streams that make them less susceptible to an economic downturn. AbbVie's size, scope will help it push past Humira patent cliff AbbVie's stock is up more than 25% over the past 12 months and more than 9% this year. On ... |
24,074 | 2021-05-24 00:00:00 UTC | Will the COVID Vaccine Companies Fall off the Patent Cliff? | ABBV | https://www.nasdaq.com/articles/will-the-covid-vaccine-companies-fall-off-the-patent-cliff-2021-05-24 | null | null | On May 5 the Biden administration announced that the government would support the removal of patent protections for COVID-19 vaccines at the World Trade Organization. "The Administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protecti... | Corinne Cardina: We saw that happened with Humira, which is owned by AbbVie. AbbVie has been losing its patent protection for Humira and they are scrambling to make that up elsewhere because they are heading toward the patent cliff. On May 5 the Biden administration announced that the government would support the remov... | Corinne Cardina: We saw that happened with Humira, which is owned by AbbVie. AbbVie has been losing its patent protection for Humira and they are scrambling to make that up elsewhere because they are heading toward the patent cliff. On May 5 the Biden administration announced that the government would support the remov... | AbbVie has been losing its patent protection for Humira and they are scrambling to make that up elsewhere because they are heading toward the patent cliff. Corinne Cardina: We saw that happened with Humira, which is owned by AbbVie. In this Motley Fool Live video, recorded on May 14, Corinne Cardina, bureau chief of he... | Corinne Cardina: We saw that happened with Humira, which is owned by AbbVie. AbbVie has been losing its patent protection for Humira and they are scrambling to make that up elsewhere because they are heading toward the patent cliff. So it's perhaps unlikely that the WTO will abolish the patent protections. |
24,075 | 2021-05-23 00:00:00 UTC | The Best Dividend Aristocrats to Buy With $500 Right Now | ABBV | https://www.nasdaq.com/articles/the-best-dividend-aristocrats-to-buy-with-%24500-right-now-2021-05-23 | null | null | Having a low budget doesn't necessarily mean you have to go with low quality. This is true for nearly anything you buy -- including dividend stocks.
The highest-quality dividend stocks have excellent track records of growing their dividends over time. Dividend Aristocrats rank as the cream of the crop. These are S&P 50... | While AbbVie hasn't delivered as great of a return as its parent company has over the last five years, it's still performed pretty well, with the stock nearly doubling. AbbVie If you like Abbott's dividend track record, you're going to like AbbVie (NYSE: ABBV) as well. AbbVie has raised its dividend by 225% since then,... | AbbVie If you like Abbott's dividend track record, you're going to like AbbVie (NYSE: ABBV) as well. AbbVie has raised its dividend by 225% since then, with its streak of dividend hikes extending to 49 years just like Abbott. However, AbbVie claims a much juicier dividend yield of over 4.4%. | AbbVie has raised its dividend by 225% since then, with its streak of dividend hikes extending to 49 years just like Abbott. AbbVie If you like Abbott's dividend track record, you're going to like AbbVie (NYSE: ABBV) as well. However, AbbVie claims a much juicier dividend yield of over 4.4%. | AbbVie If you like Abbott's dividend track record, you're going to like AbbVie (NYSE: ABBV) as well. AbbVie has raised its dividend by 225% since then, with its streak of dividend hikes extending to 49 years just like Abbott. However, AbbVie claims a much juicier dividend yield of over 4.4%. |
24,076 | 2021-05-22 00:00:00 UTC | These Top 3 Healthcare Dividend Stocks Will Carry You Through Any Market Mood | ABBV | https://www.nasdaq.com/articles/these-top-3-healthcare-dividend-stocks-will-carry-you-through-any-market-mood-2021-05-22 | null | null | In the Ice Age, mammoths were fabulous beasts of their time -- so much so that some geneticists are pursuing their revival by using new technology, such as writing DNA, to clone them back into existence. But whether or not literal mammoths are returning to a tundra near you, certain "mammoths" of the healthcare space n... | As mammoths of the healthcare industry, AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and UnitedHealth Group (NYSE: UNH) have been paying dividends for more than 10 consecutive years each (two of them for more than 45 years!). The leader The leader of this group, based on its current annual dividend and average o... | As mammoths of the healthcare industry, AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and UnitedHealth Group (NYSE: UNH) have been paying dividends for more than 10 consecutive years each (two of them for more than 45 years!). The leader The leader of this group, based on its current annual dividend and average o... | As mammoths of the healthcare industry, AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and UnitedHealth Group (NYSE: UNH) have been paying dividends for more than 10 consecutive years each (two of them for more than 45 years!). The leader The leader of this group, based on its current annual dividend and average o... | As mammoths of the healthcare industry, AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and UnitedHealth Group (NYSE: UNH) have been paying dividends for more than 10 consecutive years each (two of them for more than 45 years!). The leader The leader of this group, based on its current annual dividend and average o... |
24,077 | 2021-05-22 00:00:00 UTC | 3 Solid Stocks That Can Be Smart Picks Even in Choppy Markets | ABBV | https://www.nasdaq.com/articles/3-solid-stocks-that-can-be-smart-picks-even-in-choppy-markets-2021-05-22 | null | null | The U.S. equity market has been quite volatile over the past few weeks. The first three days of last week saw tech stocks falling on fears of increasing inflation and a faster-than-anticipated tightening monetary policy. Then, on May 13, Federal Reserve officials played down the risk of a tightening policy and claimed ... | Considering AbbVie's diversified product portfolio, balance-sheet strength, and high dividend yield, the company offers retail investors an attractive risk-reward proposition at a reasonable valuation of just 8.4 times forward earnings. While no one can predict the short-term direction of the market, retail investors c... | While no one can predict the short-term direction of the market, retail investors can convert this period of uncertainty into opportunity by investing in fundamentally strong and resilient stocks such as AT&T (NYSE: T), Apple (NASDAQ: AAPL), and AbbVie (NYSE: ABBV). AbbVie After a lackluster performance in 2020, biopha... | While no one can predict the short-term direction of the market, retail investors can convert this period of uncertainty into opportunity by investing in fundamentally strong and resilient stocks such as AT&T (NYSE: T), Apple (NASDAQ: AAPL), and AbbVie (NYSE: ABBV). AbbVie After a lackluster performance in 2020, biopha... | While no one can predict the short-term direction of the market, retail investors can convert this period of uncertainty into opportunity by investing in fundamentally strong and resilient stocks such as AT&T (NYSE: T), Apple (NASDAQ: AAPL), and AbbVie (NYSE: ABBV). AbbVie After a lackluster performance in 2020, biopha... |
24,078 | 2021-05-21 00:00:00 UTC | Best Dividend Stocks To Buy Now? 4 Trending Now | ABBV | https://www.nasdaq.com/articles/best-dividend-stocks-to-buy-now-4-trending-now-2021-05-21 | null | null | Top Dividend Stocks To Consider Adding To Your Long-Term Portfolio
Amidst the volatility seen in the stock market recently, more investors could be turning towards dividend stocks. As a result, the highest paying dividend stocks in 2021 could have more room to grow right now. While that may seem like the likely strateg... | Top Dividend Stocks To Buy [Or Avoid] Now Procter & Gamble Company (NYSE: PG) AT&T Inc. (NYSE: T) Brookfield Renewable Partners (NYSE: BEP) AbbVie Inc. (NYSE: ABBV) Procter & Gamble Company Procter & Gamble (PG) is a multinational consumer goods corporation. 5 To Watch AbbVie Inc. Another top dividend-paying company to... | Top Dividend Stocks To Buy [Or Avoid] Now Procter & Gamble Company (NYSE: PG) AT&T Inc. (NYSE: T) Brookfield Renewable Partners (NYSE: BEP) AbbVie Inc. (NYSE: ABBV) Procter & Gamble Company Procter & Gamble (PG) is a multinational consumer goods corporation. 5 To Watch AbbVie Inc. Another top dividend-paying company to... | Top Dividend Stocks To Buy [Or Avoid] Now Procter & Gamble Company (NYSE: PG) AT&T Inc. (NYSE: T) Brookfield Renewable Partners (NYSE: BEP) AbbVie Inc. (NYSE: ABBV) Procter & Gamble Company Procter & Gamble (PG) is a multinational consumer goods corporation. 5 To Watch AbbVie Inc. Another top dividend-paying company to... | 5 To Watch AbbVie Inc. Another top dividend-paying company to know now would be AbbVie Inc. Top Dividend Stocks To Buy [Or Avoid] Now Procter & Gamble Company (NYSE: PG) AT&T Inc. (NYSE: T) Brookfield Renewable Partners (NYSE: BEP) AbbVie Inc. (NYSE: ABBV) Procter & Gamble Company Procter & Gamble (PG) is a multination... |
24,079 | 2021-05-21 00:00:00 UTC | 2 Healthcare Stocks Perfect to Buy Now and Hold Until Retirement | ABBV | https://www.nasdaq.com/articles/2-healthcare-stocks-perfect-to-buy-now-and-hold-until-retirement-2021-05-21 | null | null | The best stocks are those you can buy now and hold for the long term. Two healthcare companies that fit the bill are AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). Neither company is a big participant in the COVID-19 vaccine race. They seem to have stuck to their circles of competence, and have been working to deliver f... | Two healthcare companies that fit the bill are AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie In 2013, AbbVie was spun off from Abbott Laboratories. AbbVie's product portfolio is not just made up of Humira (for rheumatoid arthritis); it also includes notable products like Imbruvica (lymphoma), Venclexta (leukemia... | All these drugs boost AbbVie's sales, and have been big drivers of its tremendous revenue growth over the past few years. Two healthcare companies that fit the bill are AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie In 2013, AbbVie was spun off from Abbott Laboratories. | All these drugs boost AbbVie's sales, and have been big drivers of its tremendous revenue growth over the past few years. Two healthcare companies that fit the bill are AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie In 2013, AbbVie was spun off from Abbott Laboratories. | All these drugs boost AbbVie's sales, and have been big drivers of its tremendous revenue growth over the past few years. Two healthcare companies that fit the bill are AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). AbbVie In 2013, AbbVie was spun off from Abbott Laboratories. |
24,080 | 2021-05-18 00:00:00 UTC | AbbVie exploits U.S. patents to protect profits: Congress report | ABBV | https://www.nasdaq.com/articles/abbvie-exploits-u.s.-patents-to-protect-profits%3A-congress-report-2021-05-18-0 | null | null | Adds comment from Janssen
WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report on Tuesday.
AbbVie Inc's chief executive... | Adds comment from Janssen WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report on Tuesday. AbbVie Inc's chief executive... | Adds comment from Janssen WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report on Tuesday. AbbVie Inc's chief executive... | Adds comment from Janssen WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report on Tuesday. AbbVie Inc's chief executive... | AbbVie Inc's chief executive officer Richard Gonzalez testifies Tuesday about Humira's price, which has increased to $77,000 for a year's supply, and the price of Imbruvica, which now costs $181,529 for a year's supply, said the committee, which called Humira "the highest grossing drug in the world." "Documents and inf... |
24,081 | 2021-05-18 00:00:00 UTC | After a Blowout Quarter, Is AbbVie Stock a Buy? | ABBV | https://www.nasdaq.com/articles/after-a-blowout-quarter-is-abbvie-stock-a-buy-2021-05-18 | null | null | Pharmaceutical giant AbbVie (NYSE: ABBV) reported earnings recently, beating estimates on revenue and earnings per share. The current state of the company is very impressive and future growth looks promising. The stock might have rallied by 40% in the last year, but let me show you why you should still consider buying ... | Analysts estimate the Parkinson's disease market could reach $5.69 billion by 2022, and the possible addition of Mitokinin to AbbVie's portfolio could help drive future growth for the pharmaceutical giant. Pharmaceutical giant AbbVie (NYSE: ABBV) reported earnings recently, beating estimates on revenue and earnings per... | Pharmaceutical giant AbbVie (NYSE: ABBV) reported earnings recently, beating estimates on revenue and earnings per share. Exceeding expectations AbbVie, along with other major pharmaceutical companies such as Bristol Myers Squibb, Merck, and Pfizer, reported quarterly results recently; it stood out among its peers, bea... | The stock might have rallied by 40% in the last year, but let me show you why you should still consider buying into AbbVie at these prices. In its Q1 2021 earnings, reported April 30, AbbVie brought in $13.01 billion, growing its first-quarter revenues 51% year over year. Pharmaceutical giant AbbVie (NYSE: ABBV) report... | The stock might have rallied by 40% in the last year, but let me show you why you should still consider buying into AbbVie at these prices. Analysts estimate the Parkinson's disease market could reach $5.69 billion by 2022, and the possible addition of Mitokinin to AbbVie's portfolio could help drive future growth for ... |
24,082 | 2021-05-18 00:00:00 UTC | AbbVie exploits U.S. patents to protect profits: Congress report | ABBV | https://www.nasdaq.com/articles/abbvie-exploits-u.s.-patents-to-protect-profits%3A-congress-report-2021-05-18 | null | null | WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday.
AbbVie Inc's chief executive officer Richard Go... | WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday. AbbVie Inc's chief executive officer Richard Go... | WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday. AbbVie Inc's chief executive officer Richard Go... | WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday. "Documents and information obtained by the comm... | WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday. AbbVie Inc's chief executive officer Richard Go... |
24,083 | 2021-05-16 00:00:00 UTC | 3 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-id-buy-right-now-2021-05-16 | null | null | Look up "yield" in the dictionary. One of the first definitions you'll find is something along the lines of to give up or surrender. Of course, investors have another meaning in mind when they think about yield. They're thinking about the dividends they can receive by buying stocks.
Unfortunately, the investing definit... | AbbVie You won't have to give up much at all investing in AbbVie (NYSE: ABBV). AbbVie's dividend yield currently stands at close to 4.5%. Many investors would also consider AbbVie a bargain. | AbbVie You won't have to give up much at all investing in AbbVie (NYSE: ABBV). AbbVie's dividend yield currently stands at close to 4.5%. Many investors would also consider AbbVie a bargain. | See the 10 stocks *Stock Advisor returns as of May 11, 2021 Keith Speights owns shares of AbbVie and Enterprise Products Partners. AbbVie You won't have to give up much at all investing in AbbVie (NYSE: ABBV). AbbVie's dividend yield currently stands at close to 4.5%. | AbbVie You won't have to give up much at all investing in AbbVie (NYSE: ABBV). AbbVie's dividend yield currently stands at close to 4.5%. Many investors would also consider AbbVie a bargain. |
24,084 | 2021-05-14 00:00:00 UTC | iShares MSCI USA Quality Factor ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-msci-usa-quality-factor-etf-experiences-big-outflow-2021-05-14 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI USA Quality Factor ETF (Symbol: QUAL) where we have detected an approximate $119.9 million dollar outflow -- that's a 0.6% decrease week over week (from 160,900,000 to 159,950,0... | Among the largest underlying components of QUAL, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, Blackrock Inc (Symbol: BLK) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the QUAL Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of QUAL, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, Blackrock Inc (Symbol: BLK) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the QUAL Holdings page » The chart below shows the one year price perf... | Among the largest underlying components of QUAL, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, Blackrock Inc (Symbol: BLK) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of QUAL, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, Blackrock Inc (Symbol: BLK) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the QUAL Holdings page » The chart below shows the one year price perf... |
24,085 | 2021-05-14 00:00:00 UTC | 3 Dividend Stocks That Pay You Better Than Coca-Cola Does | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-pay-you-better-than-coca-cola-does-2021-05-14 | null | null | It's hard to find many chinks in the armor of Coca-Cola's (NYSE: KO) renowned dividend. The company has raised it for 59 consecutive years, and at current share prices, it delivers a yield of 3%, well above the S&P 500's average yield of 1.38%.
However, when you compare it as an income investment to a few of its fellow... | However, when you compare it as an income investment to a few of its fellow Dividend Aristocrats such as AbbVie (NYSE: ABBV), Kimberly-Clark (NYSE: KMB), and Chevron (NYSE: CVX), it fizzles out. AbbVie is looking past the Humira patent cliff Pharmaceutical company AbbVie has a dividend with a yield of 4.53% at Tuesday'... | However, there are plenty of other profitable drugs in its catalog: AbbVie reported $13 billion in revenue in Q1, up 51% year over year. However, when you compare it as an income investment to a few of its fellow Dividend Aristocrats such as AbbVie (NYSE: ABBV), Kimberly-Clark (NYSE: KMB), and Chevron (NYSE: CVX), it f... | However, when you compare it as an income investment to a few of its fellow Dividend Aristocrats such as AbbVie (NYSE: ABBV), Kimberly-Clark (NYSE: KMB), and Chevron (NYSE: CVX), it fizzles out. AbbVie is looking past the Humira patent cliff Pharmaceutical company AbbVie has a dividend with a yield of 4.53% at Tuesday'... | However, when you compare it as an income investment to a few of its fellow Dividend Aristocrats such as AbbVie (NYSE: ABBV), Kimberly-Clark (NYSE: KMB), and Chevron (NYSE: CVX), it fizzles out. AbbVie is looking past the Humira patent cliff Pharmaceutical company AbbVie has a dividend with a yield of 4.53% at Tuesday'... |
24,086 | 2021-05-14 00:00:00 UTC | U.S. House panel to hold May 18 hearing over AbbVie drug pricing | ABBV | https://www.nasdaq.com/articles/u.s.-house-panel-to-hold-may-18-hearing-over-abbvie-drug-pricing-2021-05-14 | null | null | WASHINGTON, May 14 (Reuters) - AbbieVie Inc's chief executive officer will testify at a May 18 congressional hearing over the drugmaker's pricing and business practices for its anti-inflammatory drug Humira and its cancer drug Imbruvica, lawmakers said on Friday.
The hearing with CEO Richard Gonzalez will examine price... | WASHINGTON, May 14 (Reuters) - AbbieVie Inc's chief executive officer will testify at a May 18 congressional hearing over the drugmaker's pricing and business practices for its anti-inflammatory drug Humira and its cancer drug Imbruvica, lawmakers said on Friday. The hearing with CEO Richard Gonzalez will examine price... | WASHINGTON, May 14 (Reuters) - AbbieVie Inc's chief executive officer will testify at a May 18 congressional hearing over the drugmaker's pricing and business practices for its anti-inflammatory drug Humira and its cancer drug Imbruvica, lawmakers said on Friday. The hearing with CEO Richard Gonzalez will examine price... | WASHINGTON, May 14 (Reuters) - AbbieVie Inc's chief executive officer will testify at a May 18 congressional hearing over the drugmaker's pricing and business practices for its anti-inflammatory drug Humira and its cancer drug Imbruvica, lawmakers said on Friday. The hearing with CEO Richard Gonzalez will examine price... | WASHINGTON, May 14 (Reuters) - AbbieVie Inc's chief executive officer will testify at a May 18 congressional hearing over the drugmaker's pricing and business practices for its anti-inflammatory drug Humira and its cancer drug Imbruvica, lawmakers said on Friday. The hearing with CEO Richard Gonzalez will examine price... |
24,087 | 2021-05-12 00:00:00 UTC | The Best Warren Buffett Stocks to Buy With $300 Right Now | ABBV | https://www.nasdaq.com/articles/the-best-warren-buffett-stocks-to-buy-with-%24300-right-now-2021-05-12 | null | null | Suppose one of the world's greatest investors told you some of his favorite stock picks. However, there was a problem: You only had $300 to invest, and many of his stocks were too expensive for you to buy. My hunch is that you'd probably be perfectly content to scoop up a share or two of the stocks that you could affor... | AbbVie AbbVie (NYSE: ABBV) is a relatively recent addition to Buffett's list. Probably the first thing that jumps out with AbbVie is its dividend. But AbbVie also offers pretty good growth prospects over the long run. | Keith Speights owns shares of AbbVie, Apple, Bank of America, and Berkshire Hathaway (B shares). AbbVie AbbVie (NYSE: ABBV) is a relatively recent addition to Buffett's list. Probably the first thing that jumps out with AbbVie is its dividend. | Keith Speights owns shares of AbbVie, Apple, Bank of America, and Berkshire Hathaway (B shares). AbbVie AbbVie (NYSE: ABBV) is a relatively recent addition to Buffett's list. Probably the first thing that jumps out with AbbVie is its dividend. | AbbVie AbbVie (NYSE: ABBV) is a relatively recent addition to Buffett's list. Probably the first thing that jumps out with AbbVie is its dividend. But AbbVie also offers pretty good growth prospects over the long run. |
24,088 | 2021-05-11 00:00:00 UTC | AbbVie Unit To Acquire Soliton For $550M To Boost Aesthetics Unit | ABBV | https://www.nasdaq.com/articles/abbvie-unit-to-acquire-soliton-for-%24550m-to-boost-aesthetics-unit-2021-05-11 | null | null | AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S. Food and Drug Administration (FDA). The acquisition will expand the company’s body contouring treatment portfolio.
The acquisition is built around Resonic, the Rapid Acoustic Pu... | AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S. Food and Drug Administration (FDA). Health care providers will now have another option to address consumers' aesthetic concerns”, said AbbVie Senior Vice President Carrie Strom.... | AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S. Food and Drug Administration (FDA). Health care providers will now have another option to address consumers' aesthetic concerns”, said AbbVie Senior Vice President Carrie Strom.... | AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S. Food and Drug Administration (FDA). Under the terms of the deal, the AbbVie unit is to pay $22.60 per share for each Soliton’s outstanding shares, valuing the deal at about $550... | (See AbbVie stock analysis on TipRanks). AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S. Food and Drug Administration (FDA). Health care providers will now have another option to address consumers' aesthetic concerns”, said A... |
24,089 | 2021-05-10 00:00:00 UTC | Allergan Aesthetics To Buy Soliton For $22.60/Share In Cash - Quick Facts | ABBV | https://www.nasdaq.com/articles/allergan-aesthetics-to-buy-soliton-for-%2422.60-share-in-cash-quick-facts-2021-05-10 | null | null | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV) and Soliton (SOLY) announced Monday a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive tr... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV) and Soliton (SOLY) announced Monday a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive tr... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV) and Soliton (SOLY) announced Monday a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive tr... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV) and Soliton (SOLY) announced Monday a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive tr... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV) and Soliton (SOLY) announced Monday a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive tr... |
24,090 | 2021-05-10 00:00:00 UTC | Health Care Sector Update for 05/10/2021: VTRS,SOLY,ABBV,PTE,SNGX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-05-10-2021%3A-vtrssolyabbvptesngx-2021-05-10 | null | null | Health care stocks still were mostly higher this afternoon, with the NYSE Health Care Index rising 0.4% while the SPDR Health Care Select Sector ETF also was up 0.4% in late trade.
The Nasdaq Biotechnology index, however, was sinking 1.6%.
In company news, Viatris (VTRS) gained 7% after the drug maker Monday reported a... | Soliton (SOLY) rose over 25% to a best-ever $22.55 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for each Soliton share. AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an all-time high of ... | AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an all-time high of $117.18 a share. Soliton (SOLY) rose over 25% to a best-ever $22.55 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for eac... | Soliton (SOLY) rose over 25% to a best-ever $22.55 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for each Soliton share. AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an all-time high of ... | AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an all-time high of $117.18 a share. Soliton (SOLY) rose over 25% to a best-ever $22.55 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for eac... |
24,091 | 2021-05-10 00:00:00 UTC | Health Care Sector Update for 05/10/2021: SOLY,ABBV,PTE,SNGX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-05-10-2021%3A-solyabbvptesngx-2021-05-10 | null | null | Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 0.7% while the SPDR Health Care Select Sector ETF also was up 0.8%.
The Nasdaq Biotechnology index, however, was sinking 1.1%.
In company news, Soliton (SOLY) rose over 25% to a best-ever $22.53 a share after the medical device... | In company news, Soliton (SOLY) rose over 25% to a best-ever $22.53 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for each Soliton share. AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an ... | In company news, Soliton (SOLY) rose over 25% to a best-ever $22.53 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for each Soliton share. AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an ... | In company news, Soliton (SOLY) rose over 25% to a best-ever $22.53 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for each Soliton share. AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an ... | In company news, Soliton (SOLY) rose over 25% to a best-ever $22.53 a share after the medical device company agreed to a $550 million buyout offer from AbbVie's (ABBV) Allergan Aesthetics, which will pay $22.60 in cash for each Soliton share. AbbVie shares were fractionally higher, earlier rising 1.2% to also touch an ... |
24,092 | 2021-05-09 00:00:00 UTC | 3 Embarrassingly Cheap Dividend Stocks | ABBV | https://www.nasdaq.com/articles/3-embarrassingly-cheap-dividend-stocks-2021-05-09 | null | null | What's better than a dividend stock with a solid yield? A cheap dividend stock with a solid yield.
There's a problem, though. With the stock market near all-time highs, most stocks are priced at a premium. Thankfully, that's not true of every stock, though. Here are three embarrassingly cheap dividend stocks.
Image sou... | AbbVie AbbVie's (NYSE: ABBV) shares currently trade at only 9.3 times expected earnings. AbbVie's dividend yield currently stands at nearly 4.5%. Why is AbbVie such an embarrassingly cheap dividend stock? | Bristol Myers Squibb's (NYSE: BMY) shares trade at close to 8.7 times expected earnings, even lower than AbbVie's forward earnings multiple. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Viatris Inc. AbbVie AbbVie's (NYSE: ABBV) shares c... | Bristol Myers Squibb's (NYSE: BMY) shares trade at close to 8.7 times expected earnings, even lower than AbbVie's forward earnings multiple. BMS isn't a Dividend Aristocrat like AbbVie is, but its dividend should be attractive to many investors. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Spe... | BMS isn't a Dividend Aristocrat like AbbVie is, but its dividend should be attractive to many investors. AbbVie AbbVie's (NYSE: ABBV) shares currently trade at only 9.3 times expected earnings. AbbVie's dividend yield currently stands at nearly 4.5%. |
24,093 | 2021-05-08 00:00:00 UTC | Is It Too Late to Buy AbbVie Stock in 2021? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-abbvie-stock-in-2021-2021-05-08 | null | null | AbbVie (NYSE: ABBV) is one of the newer pharmaceutical companies to take the market by storm. Spun off in 2013 from its parent company, Abbott Labs, it sits at a tremendous market capitalization of a little over $200 billion. The stock has still about 5% off its all-time highs from 2018, and if AbbVie's recent first-qu... | To ease concerns about Humira's patent cliff coming in 2023, AbbVie has made acquisitions as well as developments in its own pipeline to diversify and drive growth. Growing revenue, pipeline expansion, and a cheap valuation are reasons investors shouldn't wait to pull the trigger on AbbVie. AbbVie (NYSE: ABBV) is one o... | Image source: Getty Images Earnings beat AbbVie reported its first-quarter earnings last week, and beat analyst estimates on most metrics. AbbVie's current immunology portfolio is the biggest driver of annual sales, and includes blockbuster drug Humira as well as up-and-comers Skyrizi to treat plaque psoriasis and Rinv... | AbbVie's current immunology portfolio is the biggest driver of annual sales, and includes blockbuster drug Humira as well as up-and-comers Skyrizi to treat plaque psoriasis and Rinvoq to treat rheumatoid arthritis. Growth from Humira and AbbVie's various businesses has contributed to the recent revenue growth of 47.4% ... | AbbVie's current immunology portfolio is the biggest driver of annual sales, and includes blockbuster drug Humira as well as up-and-comers Skyrizi to treat plaque psoriasis and Rinvoq to treat rheumatoid arthritis. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares of AbbVie. A... |
24,094 | 2021-05-07 00:00:00 UTC | 7 Warren Buffett Stocks to Buy for the Next Decade | ABBV | https://www.nasdaq.com/articles/7-warren-buffett-stocks-to-buy-for-the-next-decade-2021-05-07 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Nowadays, it’s very popular for younger investors to get their advice on social media forums or from YouTube financial gurus. To me, it sounds like the blind leading the blind. Every year, a new hotshot claims to have the inside path to profitable stocks to... | AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) American Express (NYSE:AXP) Charter Communications (NASDAQ:CHTR) Chevron (NYSE:CVX) Itochu Corporation (OTCMKTS:ITOCF) Verisign (NASDAQ:VRSN) Now, I should note that despite my high praise for Warren Buffett, he’s not the ultimate arbiter of equity valuations: the market is. Stoc... | AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) American Express (NYSE:AXP) Charter Communications (NASDAQ:CHTR) Chevron (NYSE:CVX) Itochu Corporation (OTCMKTS:ITOCF) Verisign (NASDAQ:VRSN) Now, I should note that despite my high praise for Warren Buffett, he’s not the ultimate arbiter of equity valuations: the market is. Stoc... | AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) American Express (NYSE:AXP) Charter Communications (NASDAQ:CHTR) Chevron (NYSE:CVX) Itochu Corporation (OTCMKTS:ITOCF) Verisign (NASDAQ:VRSN) Now, I should note that despite my high praise for Warren Buffett, he’s not the ultimate arbiter of equity valuations: the market is. Stoc... | AbbVie (NYSE:ABBV) Amazon (NASDAQ:AMZN) American Express (NYSE:AXP) Charter Communications (NASDAQ:CHTR) Chevron (NYSE:CVX) Itochu Corporation (OTCMKTS:ITOCF) Verisign (NASDAQ:VRSN) Now, I should note that despite my high praise for Warren Buffett, he’s not the ultimate arbiter of equity valuations: the market is. Stoc... |
24,095 | 2021-05-05 00:00:00 UTC | IWB, CRM, ABBV, WFC: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iwb-crm-abbv-wfc%3A-large-outflows-detected-at-etf-2021-05-05 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $93.8 million dollar outflow -- that's a 0.3% decrease week over week (from 121,650,000 to 121,250,000). Among th... | Among the largest underlying components of IWB, in trading today Salesforce.com Inc (Symbol: CRM) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Wells Fargo & Co (Symbol: WFC) is higher by about 0.1%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWB, in trading today Salesforce.com Inc (Symbol: CRM) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Wells Fargo & Co (Symbol: WFC) is higher by about 0.1%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year pr... | Among the largest underlying components of IWB, in trading today Salesforce.com Inc (Symbol: CRM) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Wells Fargo & Co (Symbol: WFC) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of IWB, in trading today Salesforce.com Inc (Symbol: CRM) is up about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Wells Fargo & Co (Symbol: WFC) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
24,096 | 2021-05-04 00:00:00 UTC | AbbVie Raises EPS Guidance After 1Q Earnings Beat | ABBV | https://www.nasdaq.com/articles/abbvie-raises-eps-guidance-after-1q-earnings-beat-2021-05-04 | null | null | AbbVie (ABBV) is off to a good start going by its impressive 1Q 2021 results. Net revenues increased by 51% year-over-year to $13.01 billion. The drug-maker generated adjusted diluted earnings per share of $2.95 as the adjusted gross margin came in at 83.9%. CEO Richard Gonzalez stated, “Our new products are delivering... | Divan told investors, “With a diversified new product story, robust near-term growth and good visibility into its longer-term growth prospects, we continue to see AbbVie as an especially compelling investment opportunity, especially when one considers the discount it trades at and its robust dividend.” The analyst has ... | In addition, Mizuho Securities analyst Vamil Divan reiterated a Buy rating on AbbVie following the strong beat in 1Q. Divan told investors, “With a diversified new product story, robust near-term growth and good visibility into its longer-term growth prospects, we continue to see AbbVie as an especially compelling inv... | (See AbbVie stock analysis on TipRanks) During the quarter, the Food and Drugs Administration (FDA) accepted AbbVie's New Drug Application for an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for migraine treatment in adults. Divan told investors, “With a diversified new produc... | AbbVie has made an application for the approval of Skyrizi, a novel treatment for adults with active psoriatic arthritis. Following the impressive 1Q results, AbbVie's management raised its guidance for the full year. AbbVie (ABBV) is off to a good start going by its impressive 1Q 2021 results. |
24,097 | 2021-05-03 00:00:00 UTC | This Is Why Humira Isn't AbbVie's Biggest Problem Right Now | ABBV | https://www.nasdaq.com/articles/this-is-why-humira-isnt-abbvies-biggest-problem-right-now-2021-05-03 | null | null | Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Ab... | Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. Overcoming Humira's far-off ... | Class effect Unfortunately for AbbVie, competition for leukemia patients from next-generation BTK inhibitors is about to rise exponentially. AbbVie's Rinvoq is a new JAK inhibitor the FDA approved to treat rheumatoid arthritis in 2019. Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) l... | The beginning of Imbruvica's end In 2015, AbbVie acquired Pharmacyclics for about $21 billion to gain rights to the portion of sales for Imbruvica, a new cancer drug that Johnson & Johnson (NYSE: JNJ) already owned part of. Don't panic Right now, you can find better pharma stocks to buy than AbbVie, but you shouldn't d... | Class effect Unfortunately for AbbVie, competition for leukemia patients from next-generation BTK inhibitors is about to rise exponentially. Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-p... |
24,098 | 2021-05-03 00:00:00 UTC | AbbVie Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-beat-analyst-estimates%3A-see-what-the-consensus-is-forecasting-for-this-year | null | null | The quarterly results for AbbVie Inc. (NYSE:ABBV) were released last week, making it a good time to revisit its performance. Revenues were US$13b, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$1.99, an impressive 36% ahead of esti... | The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for AbbVie. The quarterly results for AbbVie Inc. (NYSE:ABBV) were released last week, making it a good time to revisit its performance. Readers will be glad to know we've a... | NYSE:ABBV Earnings and Revenue Growth May 3rd 2021 Taking into account the latest results, the consensus forecast from AbbVie's 20 analysts is for revenues of US$55.7b in 2021, which would reflect a notable 11% improvement in sales compared to the last 12 months. It's clear that while AbbVie's revenue growth is expecte... | NYSE:ABBV Earnings and Revenue Growth May 3rd 2021 Taking into account the latest results, the consensus forecast from AbbVie's 20 analysts is for revenues of US$55.7b in 2021, which would reflect a notable 11% improvement in sales compared to the last 12 months. We can infer from the latest estimates that forecasts ex... | It's clear that while AbbVie's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself. The quarterly results for AbbVie Inc. (NYSE:ABBV) were released last week, making it a good time to revisit its performance. Readers will be glad to know we've ag... |
24,099 | 2021-05-02 00:00:00 UTC | Warren Buffett's 3 Highest-Yielding Dividend Stocks | ABBV | https://www.nasdaq.com/articles/warren-buffetts-3-highest-yielding-dividend-stocks-2021-05-02 | null | null | Warren Buffett loves dividends. That's true even though his own Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) has never initiated a dividend program.
Some of the stocks Berkshire owns don't offer dividends, but many of them do. And a handful of them pay juicy yields that would be attractive to any income investor. Her... | Although AbbVie does expect declining sales for Humira will cause its overall revenue to fall in 2023, the company projects a return to growth the following year. AbbVie AbbVie (NYSE: ABBV) is another Dividend Aristocrat in Buffett's Berkshire holdings. AbbVie's dividend yield currently stands at nearly 4.7%. | AbbVie AbbVie (NYSE: ABBV) is another Dividend Aristocrat in Buffett's Berkshire holdings. AbbVie's dividend yield currently stands at nearly 4.7%. AbbVie certainly appears to be a bargain right now with its shares trading at only nine times expected earnings. | See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Chevron. AbbVie AbbVie (NYSE: ABBV) is another Dividend Aristocrat in Buffett's Berkshire holdings. AbbVie's dividend yield currently stands at nearly 4.7%. | AbbVie AbbVie (NYSE: ABBV) is another Dividend Aristocrat in Buffett's Berkshire holdings. AbbVie's dividend yield currently stands at nearly 4.7%. AbbVie certainly appears to be a bargain right now with its shares trading at only nine times expected earnings. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.